• Male

Prof. dr. J.M.F.G. Aerts PhD

Position:
Main activities: Research, Teaching
Specialisation:
foto
Focus of research:

Glycosphingolipids in health and disease.

  • Therapy and pathophysiology of inherited glycosphingolipid storage disorders, metabolic syndrome and neurodegenerative diseases.
  • Biomarker discovery and characterization by quantitative proteomics and lipidomics. 
AMC themes: Cardiovascular Diseases, Metabolic disorders and gastrointestinal diseases
Departments: Medical Biochemistry
Avula T. Role of SH3 and BAR domains in fission yeast. S.l.: s.n.; 2017. 245p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Hochstenbach FMH, Distel B)
Ben Bdira F, Kallemeijn WW, Oussoren SV, Scheij S, Bleijlevens B, Florea BI, van Roomen CPAA, Ottenhoff R, van Kooten MJFM, Walvoort MTC, Witte MD, Boot RG, Ubbink M, Overkleeft HS, Aerts JMFG, Stabilization of Glucocerebrosidase by Active Site Occupancy. ACS CHEM BIOL 2017;12 (7):1830-1841 [PubMed]
Gabriel TL. Lysosomal stress: a new player in perturbed lipid metabolism. S.l.: s.n.; 2017. 209p. ISBN 978-94-91602-96-2 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): van Eijk MC)
Gabriel TL, Mirzaian M, Hooibrink B, Ottenhoff R, van Roomen C, Aerts JMFG, van Eijk M, Induction of Sphk1 activity in obese adipose tissue macrophages promotes survival. PLOS ONE 2017;12 (7):e0182075 [PubMed]
Gkourtsa A. Understanding the role of BAR and SH3 domain-containing proteins in fungi. S.l.: s.n.; 2017. 243p. ISBN 978-90-77595-88-6 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Distel B, Hochstenbach FMH)
Guimarães da Lomba Ferraz MJ. Glycosphingolipidoses: Enzymes and their lipids. S.l.: s.n.; 2017. 290p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JFMG; copromotor(s): Boot RG)
Herrera Moro Chao D. Glycosphingolipids and the central regulation of metabolism: Sugar analogues as research tools. S.l.: s.n.; 2017. 277p. ISBN 978-94-91602-86-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, Kalsbeek A; copromotor(s): van Eijk MC, Boot RG)
Jiang J, Kuo CL, Wu L, Franke C, Kallemeijn WW, Florea BI, van Meel E, van der Marel GA, Codée JDC, Boot RG, Davies GJ, Overkleeft HS, Aerts JMFG, Correction to "Detection of Active Mammalian GH31 α-Glucosidases in Health and Disease Using In-Class, Broad-Spectrum Activity-Based Probes". ACS CENTRAL SCI 2017;3 (6):673 [PubMed]
Kallemeijn WW, Scheij S, Hoogendoorn S, Witte MD, Herrera Moro Chao D, van Roomen CPAA, Ottenhoff R, Overkleeft HS, Boot RG, Aerts JMFG, Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes. PLOS ONE 2017;12 (2):e0170268 [PubMed]
Kytidou K, Beenakker TJM, Westerhof LB, Hokke CH, Moolenaar GF, Goosen N, Mirzaian M, Ferraz MJ, de Geus M, Kallemeijn WW, Overkleeft HS, Boot RG, Schots A, Bosch D, Aerts JMFG, Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease. FRONT PLANT SCI 2017;8:1026 [PubMed]
Lahav D, Liu B, van den Berg RJBHN, van den Nieuwendijk AMCH, Wennekes T, Ghisaidoobe AT, Breen I, Ferraz MJ, Kuo CL, Wu L, Geurink PP, Ovaa H, van der Marel GA, van der Stelt M, Boot RG, Davies GJ, Aerts JMFG, Overkleeft HS, A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase. J AM CHEM SOC 2017;139 (40):14192-14197 [PubMed]
Marques ARA, Willems LI, Herrera Moro D, Florea BI, Scheij S, Ottenhoff R, van Roomen CPAA, Verhoek M, Nelson JK, Kallemeijn WW, Biela-Banas A, Martin OR, Cachón-González MB, Kim NN, Cox TM, Boot RG, Overkleeft HS, Aerts JMFG, A Specific Activity-Based Probe to Monitor Family GH59 Galactosylceramidase, the Enzyme Deficient in Krabbe Disease. CHEMBIOCHEM 2017;18 (4):402-412 [PubMed]
Schröder SP, van de Sande JW, Kallemeijn WW, Kuo CL, Artola M, van Rooden EJ, Jiang J, Beenakker TJM, Florea BI, Offen WA, Davies GJ, Minnaard AJ, Aerts JMFG, Codée JDC, van der Marel GA, Overkleeft HS, Towards broad spectrum activity-based glycosidase probes: synthesis and evaluation of deoxygenated cyclophellitol aziridines. CHEM COMMUN 2017;53 (93):12528-12531 [PubMed]
Wu L, Jiang J, Jin Y, Kallemeijn WW, Kuo CL, Artola M, Dai W, van Elk C, van Eijk M, van der Marel GA, Codée JDC, Florea BI, Aerts JMFG, Overkleeft HS, Davies GJ, Activity-based probes for functional interrogation of retaining β-glucuronidases. NAT CHEM BIOL 2017;13 (8):867-873 [PubMed]
Ben Bdira F, Jiang J, Kallemeijn W, de Haan A, Florea BI, Bleijlevens B, Boot R, Overkleeft HS, Aerts JM, Ubbink M, Hydrophobic Interactions Contribute to Conformational Stabilization of Endoglycoceramidase II by Mechanism-Based Probes. BIOCHEMISTRY-US 2016;55 (34):4823-4835 [PubMed]
Ferraz MJ, Marques ARA, Appelman MD, Verhoek M, Strijland A, Mirzaian M, Scheij S, Ouairy CM, Lahav D, Wisse P, Overkleeft HS, Boot RG, Aerts JM, Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases. FEBS LETT 2016;590 (6):716-725 [PubMed]
Ferraz MJ, Marques ARA, Gaspar P, Mirzaian M, van Roomen C, Ottenhoff R, Alfonso P, Irún P, Giraldo P, Wisse P, Sá Miranda C, Overkleeft HS, Aerts JM, Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. MOL GENET METAB 2016;117 (2):186-193 [PubMed]
Herrera Moro Chao D, Argmann C, van Eijk M, Boot RG, Ottenhoff R, van Roomen C, Foppen E, Siljee JE, Unmehopa UA, Kalsbeek A, Aerts JMFG, Impact of obesity on taste receptor expression in extra-oral tissues: emphasis on hypothalamus and brainstem. SCI REP-UK 2016;6:29094 [PubMed]
Jiang J, Kuo CL, Wu L, Franke C, Kallemeijn WW, Florea BI, van Meel E, van der Marel GA, Codée JDC, Boot RG, Davies GJ, Overkleeft HS, Aerts JMFG, Detection of Active Mammalian GH31 alpha-Glucosidases in Health and Disease Using In-Class, Broad-Spectrum Activity-Based Probes. ACS CENTRAL SCI 2016;2 (5):351-358 [PubMed]
Kallemeijn WW, Scheij S, Voorn-Brouwer TM, Witte MD, Verhoek M, Overkleeft HS, Boot RG, Aerts JMFG, Endo-β-Glucosidase Tag Allows Dual Detection of Fusion Proteins by Fluorescent Mechanism-Based Probes and Activity Measurement. CHEMBIOCHEM 2016;17 (18):1698-1704 [PubMed]
Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M, Nelson J, Gabriel T, Kallemeijn W, Boot RG, Laman JD, Vissers JPC, Cox T, Pavlova E, Moran MT, Aerts JM, van Eijk M, Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS OPEN BIO 2016;6 (9):902-913 [PubMed]
Laigre E, Hazelard D, Casas J, Serra-Vinardell J, Michelakakis H, Mavridou I, Aerts JMFG, Delgado A, Compain P, Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease. CARBOHYD RES 2016;429:98-104 [PubMed]
Marques ARA. Lysosomal glycosidases and glycosphingolipids: New avenues for research. S.l.: s.n.; 2016. 322p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): van Eijk MC, Boot RG)
Marques ARA, Gabriel TL, Aten J, van Roomen CPAA, Ottenhoff R, Claessen N, Alfonso P, Irún P, Giraldo P, Aerts JMFG, van Eijk M, Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease. PLOS ONE 2016;11 (1):e0147208 [PubMed]
Marques ARA, Mirzaian M, Akiyama H, Wisse P, Ferraz MJ, Gaspar P, Ghauharali-van der Vlugt K, Meijer R, Giraldo P, Alfonso P, Irún P, Dahl M, Karlsson S, Pavlova EV, Cox TM, Scheij S, Verhoek M, Ottenhoff R, van Roomen CPAA, Pannu NS, van Eijk M, Dekker N, Boot RG, Overkleeft HS, Blommaart E, Hirabayashi Y, Aerts JM, Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular β-glucosidases. J LIPID RES 2016;57 (3):451-463 [PubMed]
Mirzaian M, Wisse P, Ferraz MJ, Marques ARA, Gabriel TL, van Roomen CPAA, Ottenhoff R, van Eijk M, Codée JDC, van der Marel GA, Overkleeft HS, Aerts JM, Accurate quantification of sphingosine-1-phosphate in normal and Fabry disease plasma, cells and tissues by LC-MS/MS with (13)C-encoded natural S1P as internal standard. CLIN CHIM ACTA 2016;459:36-44 [PubMed]
Moraitou M, Dermentzaki G, Dimitriou E, Monopolis I, Dekker N, Aerts H, Stefanis L, Michelakakis H, α-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. NEUROSCI LETT 2016;613:1-5 [PubMed]
Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM, Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. ORPHANET J RARE DIS 2016;11 (1):28 [PubMed]
Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C, Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, Dorn GW 2nd, Argmann CA, Verhoeven AJ, A PPARγ-Bnip3 Axis Couples Adipose Mitochondrial Fusion-Fission Balance to Systemic Insulin Sensitivity. DIABETES 2016;65 (9):2591-2605 [PubMed]
Baartscheer A, Schumacher CA, Wekker V, Verkerk AO, Veldkamp MW, van Oort RJ, Elzenaar I, Ottenhoff R, van Roomen C, Aerts H, Coronel R, Dyscholesterolemia Protects Against Ischemia-Induced Ventricular Arrhythmias. CIRC-ARRHYTHMIA ELEC 2015;8 (6):1481-1490 [PubMed]
Brackeva B, de Punt V, Kramer G, Costa O, Verhaeghen K, Stangé G, Sadones J, Xavier C, Aerts JMFG, Gorus FK, Martens GA, Potential of UCHL1 as biomarker for destruction of pancreatic beta cells. J PROTEOMICS 2015;117:156-167 [PubMed]
Dahl M, Doyle A, Olsson K, Månsson JE, Marques ARA, Mirzaian M, Aerts JM, Ehinger M, Rothe M, Modlich U, Schambach A, Karlsson S, Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice. MOL THER 2015;23 (5):835-844 [PubMed]
Herrera Moro Chao D, Kallemeijn WW, Marques ARA, Orre M, Ottenhoff R, van Roomen C, Foppen E, Renner MC, Moeton M, van Eijk M, Boot RG, Kamphuis W, Hol EM, Aten J, Overkleeft HS, Kalsbeek A, Aerts JMFG, Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes. PLOS ONE 2015;10 (9):e0138107 [PubMed]
Hoogendoorn S, Mock ED, Strijland A, Donker-Koopman WE, van den Elst H, van den Berg RJBHN, Aerts JMFG, van der Marel GA, Overkleeft HS, ortho-Carborane-Modified N-Substituted Deoxynojirimycins. EUR J ORG CHEM 2015;2015 (20):4437-4446
Jebbink JM, Boot RG, Keijser R, Moerland PD, Aten J, Veenboer GJM, van Wely M, Buimer M, Ver Loren van Themaat E, Aerts JMFG, van der Post JAM, Afink GB, Ris-Stalpers C, Increased glucocerebrosidase expression and activity in preeclamptic placenta. PLACENTA 2015;36 (2):160-169 [PubMed]
Jiang J, Beenakker TJM, Kallemeijn WW, van der Marel GA, van den Elst H, Codée JDC, Aerts JMFG, Overkleeft HS, Comparing Cyclophellitol N-Alkyl and N-Acyl Cyclophellitol Aziridines as Activity-Based Glycosidase Probes. CHEM-EUR J 2015;21 (30):10861-10869 [PubMed]
Jiang J, Kallemeijn WW, Wright DW, van den Nieuwendijk AMCH, Rohde VC, Folch EC, van den Elst H, Florea BI, Scheij S, Donker-Koopman WE, Verhoek M, Li N, Schurmann M, Mink D, Boot RG, Codee JDC, van der Marel GA, Davies GJ, Aerts JMFG, Overkleeft HS, In vitro and in vivo comparative and competitive activity-based protein profiling of GH29 alpha-L-fucosidases. CHEM SCI 2015;6 (5):2782-2789
Kramer G, Woolerton Y, van Straalen JP, Vissers JPC, Dekker N, Langridge JI, Beynon RJ, Speijer D, Sturk A, Aerts JMFG, Accuracy and Reproducibility in Quantification of Plasma Protein Concentrations by Mass Spectrometry without the Use of Isotopic Standards. PLOS ONE 2015;10 (10):e0140097 [PubMed]
Marques ARA, Aten J, Ottenhoff R, van Roomen CPAA, Herrera Moro D, Claessen N, Vinueza Veloz MF, Zhou K, Lin Z, Mirzaian M, Boot RG, de Zeeuw CI, Overkleeft HS, Yildiz Y, Aerts JMFG, Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice. PLOS ONE 2015;10 (8):e0135889 [PubMed]
Mirzaian M, Wisse P, Ferraz MJ, Gold H, Donker-Koopman WE, Verhoek M, Overkleeft HS, Boot RG, Kramer G, Dekker N, Aerts JMFG, Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard. BLOOD CELL MOL DIS 2015;54 (4):307-314 [PubMed]
Ouairy CMJ, Ferraz MJ, Boot RG, Baggelaar MP, van der Stelt M, Appelman M, van der Marel GA, Florea BI, Aerts JMFG, Overkleeft HS, Development of an acid ceramidase activity-based probe. CHEM COMMUN 2015;51 (28):6161-6163 [PubMed]
Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, Cox TM, Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J PATHOL 2015;235 (1):113-124 [PubMed]
van den Berg RJBHN, van Rijssel ER, Ferraz MJ, Houben J, Strijland A, Donker-Koopman WE, Wennekes T, Bonger KM, Ghisaidoobe ABT, Hoogendoorn S, van der Marel GA, Codée JDC, Overkleeft HS, Aerts JMFG, Synthesis and Evaluation of Hybrid Structures Composed of Two Glucosylceramide Synthase Inhibitors. CHEMMEDCHEM 2015;10 (12):2042-2062 [PubMed]
Wisse P, de Geus MAR, Cross G, van den Nieuwendijk AMCH, van Rooden EJ, van den Berg RJBHN, Aerts JMFG, van der Marel GA, Codée JDC, Overkleeft HS, Synthesis of 6-Hydroxysphingosine and alpha-Hydroxy Ceramide Using a Cross-Metathesis Strategy. J ORG CHEM 2015;80 (14):7258-7265 [PubMed]
Wisse P, Gold H, Mirzaian M, Ferraz MJ, Lutteke G, van den Berg RJBHN, van den Elst H, Lugtenburg J, van der Marel GA, Aerts JMFG, Codee JDC, Overkleeft HS, Synthesis of a Panel of Carbon-13-Labelled (Glyco)Sphingolipids. EUR J ORG CHEM 2015;2015 (12):2661-2677
Duivenvoorden BA, Ghauharali K, Scheij S, Boot RG, Aerts JMFG, van der Marel GA, Overkleeft HS, Codée JDC, Design and synthesis of 4'-O-alkyl-chitobiosyl-4-methylumbelliferone as human chitinase fluorogenic substrates. CARBOHYD RES 2014;399:26-37 [PubMed]
Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P, Boot RG, Willems LI, Overkleeft HS, Aerts JM, Gaucher disease and Fabry disease: New markers and insights in pathophysiology for two distinct glycosphingolipidoses. BBA-MOL CELL BIOL L 2014;1841 (5):811-825 [PubMed]
Gabriel TL, Tol MJ, Ottenhof R, van Roomen C, Aten J, Claessen N, Hooibrink B, de Weijer B, Serlie MJ, Argmann C, van Elsenburg L, Aerts JMFG, van Eijk M, Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent Gpnmb induction. DIABETES 2014;63 (10):3310-3323 [PubMed]
Gaspar P, Kallemeijn WW, Strijland A, Scheij S, van Eijk M, Aten J, Overkleeft HS, Balreira A, Zunke F, Schwake M, Sá Miranda C, Aerts JMFG, Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. J LIPID RES 2014;55 (1):138-145 [PubMed]
Ghisaidoobe AT, van den Berg RJBHN, Butt SS, Strijland A, Donker-Koopman WE, Scheij S, van den Nieuwendijk AMCH, Koomen GJ, van Loevezijn A, Leemhuis M, Wennekes T, van der Stelt M, van der Marel GA, van Boeckel CAA, Aerts JMFG, Overkleeft HS, Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors. J MED CHEM 2014;57 (21):9096-9104 [PubMed]
Kallemeijn WW. Activity-based probes for retaining β-glucosidases: Novel tools for research and diagnostics. s.l.: s.n.; 2014. 309p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JFMG; copromotor(s): Boot RG)
Kallemeijn WW, Witte MD, Voorn-Brouwer TM, Walvoort MTC, Li KY, Codée JDC, van der Marel GA, Boot RG, Overkleeft HS, Aerts JMFG, A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining β-glucosidases. J BIOL CHEM 2014;289 (51):35351-35362 [PubMed]
Kallemeijn WW, Witte MD, Wennekes T, Aerts JMFG, MECHANISM-BASED INHIBITORS OF GLYCOSIDASES: DESIGN AND APPLICATIONS. ADV CARBOHYD CHEM BI 2014;71:297-338 [PubMed]
Li KY, Jiang J, Witte MD, Kallemeijn WW, Donker-Koopman WE, Boot RG, Aerts JMFG, Codée JDC, van der Marel GA, Overkleeft HS, Exploring functional cyclophellitol analogues as human retaining beta-glucosidase inhibitors. ORG BIOMOL CHEM 2014;12 (39):7786-7791 [PubMed]
Li KY, Jiang J, Witte MD, Kallemeijn WW, van den Elst H, Wong CS, Chander SD, Hoogendoorn S, Beenakker TJM, Codee JDC, Aerts JMFG, van der Marel GA, Overkleeft HS, Synthesis of Cyclophellitol, Cyclophellitol Aziridine, and Their Tagged Derivatives. EUR J ORG CHEM 2014;2014 (27):6030-6043
Martens GA, Motté E, Kramer G, Stangé G, Gaarn LW, Hellemans K, Nielsen JH, Aerts JM, Ling Z, Pipeleers D, Functional characteristics of neonatal rat β cells with distinct markers. J MOL ENDOCRINOL 2014;52 (1):11-28 [PubMed]
Moraitou M, Dimitriou E, Dekker N, Monopolis I, Aerts J, Michelakakis H, Gaucher disease: plasmalogen levels in relation to primary lipid abnormalities and oxidative stress. BLOOD CELL MOL DIS 2014;53 (1-2):30-33 [PubMed]
Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lüllmann-Rauch R, Kallemeijn WW, Gaspar P, Aerts JM, Glatzel M, Saftig P, Krainc D, Schwake M, Blanz J, LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. P NATL ACAD SCI USA 2014;111 (43):15573-15578 [PubMed]
Serra-Vinardell J, Díaz L, Casas J, Grinberg D, Vilageliu L, Michelakakis H, Mavridou I, Aerts JMFG, Decroocq C, Compain P, Delgado A, Glucocerebrosidase enhancers for selected Gaucher disease genotypes by modification of α-1-C-substituted imino-D-xylitols (DIXs) by click chemistry. CHEMMEDCHEM 2014;9 (8):1744-1754 [PubMed]
Serra-Vinardell J, Díaz L, Guitiérrez-de Terán H, Sánchez-Ollé G, Bujons J, Michelakakis H, Mavridou I, Aerts JMFG, Delgado A, Grinberg D, Vilageliu L, Casas J, Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease. INT J BIOCHEM CELL B 2014;54 (C):245-254 [PubMed]
Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JMFG, Hollak CEM, Shayman JA, Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. KIDNEY INT 2014;86 (1):58-66 [PubMed]
Sorrentino V. Regulation of cholesterol metabolism: An IDOL-dependent pathway to degrade the LDL-receptor. S.l.: s.n.; 2014. 130p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Zelcer N)
Tan YL, Genereux JC, Pankow S, Aerts JMFG, Yates JR 3rd, Kelly JW, ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. CHEM BIOL 2014;21 (8):967-976 [PubMed]
van Dussen L. Twenty years of treatment for Gaucher disease: emerging challenges. s.l: s.n.; 2014. 349p. ISBN 9789461086013 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Hollak CEM, Aerts JMFG; copromotor(s): Maas M)
van Dussen L, Hendriks EJ, Groener JEM, Boot RG, Hollak CEM, Aerts JMFG, Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J INHERIT METAB DIS 2014;37 (6):991-1001 [PubMed]
Wegdam W, Argmann CA, Kramer G, Vissers JP, Buist MR, Kenter GG, Aerts JMFG, Meijer D, Moerland PD, Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors. PLOS ONE 2014;9 (9):e108046-(12 p.) [PubMed]
Willems LI, Beenakker TJM, Murray B, Gagestein B, van den Elst H, van Rijssel ER, Codee JDC, Kallemeijn WW, Aerts JMFG, van der Marel GA, Overkleeft HS, Synthesis of alpha- and beta-Galactopyranose-Configured Isomers of Cyclophellitol and Cyclophellitol Aziridine. EUR J ORG CHEM 2014;2014 (27):6044-6056
Willems LI, Beenakker TJM, Murray B, Scheij S, Kallemeijn WW, Boot RG, Verhoek M, Donker-Koopman WE, Ferraz MJ, van Rijssel ER, Florea BI, Codée JDC, van der Marel GA, Aerts JMFG, Overkleeft HS, Potent and selective activity-based probes for GH27 human retaining α-galactosidases. J AM CHEM SOC 2014;136 (33):11622-11625 [PubMed]
Willems LI, Jiang J, Li KY, Witte MD, Kallemeijn WW, Beenakker TJN, Schröder SP, Aerts JMFG, van der Marel GA, Codée JDC, Overkleeft HS, From Covalent Glycosidase Inhibitors to Activity-Based Glycosidase Probes. CHEM-EUR J 2014;20 (35):10864-10872 [PubMed]
Brands M, van Raalte DH, João Ferraz M, Sauerwein HP, Verhoeven AJ, Aerts JMFG, Diamant M, Serlie MJ, No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men. J CLIN ENDOCR METAB 2013;98 (3):1219-1225 [PubMed]
Gold H, Mirzaian M, Dekker N, Joao Ferraz M, Lugtenburg J, Codée JDC, van der Marel GA, Overkleeft HS, Linthorst GE, Groener JEM, Aerts JM, Poorthuis BJHM, Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry. CLIN CHEM 2013;59 (3):547-556 [PubMed]
Jiang L, Brackeva B, Ling Z, Kramer G, Aerts JM, Schuit F, Keymeulen B, Pipeleers D, Gorus F, Martens GA, Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo. DIABETES 2013;62 (8):2683-2688 [PubMed]
Lombardo E. Glycosphingolipids and atherosclerosis. s.l.: s.n.; 2013. 223p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Groen AK, Bietrix FMDF)
Pavlova EV, Wang SZ, Archer J, Dekker N, Aerts JMFG, Karlsson S, Cox TM, B cell lymphoma and myeloma in murine Gaucher's disease. J PATHOL 2013;231 (1):88-97 [PubMed]
Rombach SM. Fabry meets Markov. Evaluating biochemistry, disease course and costs in support of health care policy. s.l.: s.n.; 2013. 247p. ISBN 9789090273198 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, Hollak CEM; copromotor(s): Linthorst GE, Dijkgraaf MGW)
van Dussen L, Zimran A, Akkerman EM, Aerts JMFG, Petakov M, Elstein D, Rosenbaum H, Aviezer D, Brill-Almon E, Chertkoff R, Maas M, Hollak CEM, Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. BLOOD CELL MOL DIS 2013;50 (3):206-211 [PubMed]
Vlassaks E, Mencarelli C, Nikiforou M, Strackx E, Ferraz MJ, Aerts JM, de Baets MH, Martinez-Martinez P, Gavilanes AWD, Fetal asphyxia induces acute and persisting changes in the ceramide metabolism in rat brain. J LIPID RES 2013;54 (7):1825-1833 [PubMed]
Aerts JMFG, Ferraz MJ, Boot RG, van Breemen MJ, Dekker N, Kramer G, Hollak CEM, Maas M, Linthorst GE, Smid B, Rombach SM, van Dussen L, Poorthuis B, Groener JEM. Biomarkers for Lysosomal Storage Disorders in: Surendran S, editors. Neurochemistry of Metabolic Diseases: Lysosomal Storage Diseases, Phenylketonuria and Canavan Disease. Hauppage, New York: Nova Science Publishers; 2012., p. 169-203
Aureli M, Bassi R, Loberto N, Regis S, Prinetti A, Chigorno V, Aerts JM, Boot RG, Filocamo M, Sonnino S, Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts. J INHERIT METAB DIS 2012;35 (6):1081-1091 [PubMed]
Biegstraaten M, Hollak CEM, Bakkers M, Faber CG, Aerts JMFG, van Schaik IN, Small fiber neuropathy in Fabry disease. MOL GENET METAB 2012;106 (2):135-141 [PubMed]
Hollak CEM, de Sonnaville ESV, Cassiman D, Linthorst GE, Groener JE, Morava E, Wevers RA, Mannens M, Aerts JMFG, Meersseman W, Akkerman E, Niezen-Koning KE, Mulder MF, Visser G, Wijburg FA, Lefeber D, Poorthuis BJHM, Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: Disease spectrum and natural course in attenuated patients. MOL GENET METAB 2012;107 (3):526-533 [PubMed]
Kallemeijn WW, Li KY, Witte MD, Marques ARA, Aten J, Scheij S, Jiang J, Willems LI, Voorn-Brouwer TM, van Roomen CPAA, Ottenhoff R, Boot RG, van den Elst H, Walvoort MTC, Florea BI, Codée JDC, van der Marel GA, Aerts JMFG, Overkleeft HS, Novel Activity-Based Probes for Broad-Spectrum Profiling of Retaining beta-Exoglucosidases In Situ and In Vivo. ANGEW CHEM INT EDIT 2012;51 (50):12529-12533 [PubMed]
Langeveld M, van den Berg SAA, Bijl N, Bijland S, van Roomen CP, Houben-Weerts JH, Ottenhoff R, Houten SM, van Dijk KW, Romijn JA, Groen AK, Aerts JM, Voshol PJ, Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation. METABOLISM 2012;61 (1):99-107 [PubMed]
Lombardo E, van Roomen CPAA, van Puijvelde GH, Ottenhoff R, van Eijk M, Aten J, Kuiper J, Overkleeft HS, Groen AK, Verhoeven AJ, Aerts JMFG, Bietrix F, Correction of Liver Steatosis by a Hydrophobic Iminosugar Modulating Glycosphingolipids Metabolism. PLOS ONE 2012;7 (10):e38520-(10 p.) [PubMed]
Lo SM, Choi M, Liu J, Jain D, Boot RG, Kallemeijn WW, Aerts JMFG, Pashankar F, Kupfer GM, Mane S, Lifton RP, Mistry PK, Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. BLOOD 2012;119 (20):4731-4740 [PubMed]
Nietupski JB, Pacheco JJ, Chuang WL, Maratea K, Li L, Foley J, Ashe KM, Cooper CGF, Aerts JMFG, Copeland DP, Scheule RK, Cheng SH, Marshall J, Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. MOL GENET METAB 2012;105 (4):621-628 [PubMed]
Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CEM, Linthorst GE, Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome. PLOS ONE 2012;7 (10):e47805-(7 p.) [PubMed]
Rombach SM, van den Bogaard B, de Groot E, Groener JEM, Poorthuis BJ, Linthorst GE, van den Born BJH, Hollak CEM, Aerts JMFG, Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine. HYPERTENSION 2012;60 (4):998-1005 [PubMed]
van den Nieuwendijk AMCH, van den Berg RJBHN, Ruben M, Witte MD, Brussee J, Boot RG, van der Marel GA, Aerts JMFG, Overkleeft HS, Synthesis of Eight 1-Deoxynojirimycin Isomers from a Single Chiral Cyanohydrin. EUR J ORG CHEM 2012;2012 (18):3437-3446
van Dussen L, Cox TM, Hendriks EJ, Morris E, Akkerman EM, Maas M, Groener JEM, Aerts JMFG, Deegan PB, Hollak CEM, Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. HAEMATOLOGICA 2012;97 (12):1850-1854 [PubMed]
Vrins CLJ, Bietrix F, Lombardo E, van Roomen CPAA, Ottenhoff R, Overkleeft HS, Aerts JM, Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption. CLIN LIPIDOL 2012;7 (2):241-248
Vrins CLJ, Ottenhoff R, van den Oever K, de Waart DR, Kruyt JK, Zhao Y, van Berkel TJC, Havekes LM, Aerts JM, van Eck M, Rensen PCN, Groen AK, Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J LIPID RES 2012;53 (10):2017-2023 [PubMed]
Walvoort MTC, Kallemeijn WW, Willems LI, Witte MD, Aerts JMFG, van der Marel GA, Codée JDC, Overkleeft HS, Tuning the leaving group in 2-deoxy-2-fluoroglucoside results in improved activity-based retaining beta-glucosidase probes. CHEM COMMUN 2012;48 (84):10386-10388 [PubMed]
Wegdam W, Moerland PD, Meijer D, de Jong SM, Hoefsloot HCJ, Kenter GG, Buist MR, Aerts JMFG, A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. PROTEOME SCI 2012;10 (1):45-(10 p.) [PubMed]
Wennekes T, Bonger KM, Vogel K, van den Berg RJBHN, Strijland A, Donker-Koopman WE, Aerts JMFG, van der Marel GA, Overkleeft HS, The Development of an Aza-C-Glycoside Library Based on a Tandem Staudinger/Aza-Wittig/Ugi Three-Component Reaction. EUR J ORG CHEM 2012;2012 (32):6420-6454
Zhang CK, Stein PB, Liu J, Wang Z, Yang R, Cho JH, Gregersen PK, Aerts JMFG, Zhao H, Pastores GM, Mistry PK, Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. AM J HEMATOL 2012;87 (4):377-383 [PubMed]
Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS, Glycosphingolipids and insulin resistance. ADV EXP MED BIOL 2011;721:99-119 [PubMed]
Aerts JMFG, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, Kramer G, Poorthuis BJ, Groener JEM, Cox-Brinkman J, Rombach SM, Hollak CEM, Linthorst GE, Witte MD, Gold H, van der Marel GA, Overkleeft HS, Boot RG, Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J INHERIT METAB DIS 2011;34 (3):605-619 [PubMed]
Ashe KM, Bangari D, Li L, Cabrera-Salazar MA, Bercury SD, Nietupski JB, Cooper CGF, Aerts JMFG, Lee ER, Copeland DP, Cheng SH, Scheule RK, Marshall J, Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLOS ONE 2011;6 (6):e21758 [PubMed]
Bakermans AJ, Geraedts TR, van Weeghel M, Denis S, João Ferraz M, Aerts JMFG, Aten J, Nicolay K, Houten SM, Prompers JJ, Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by impaired left ventricular function. CIRC-CARDIOVASC IMAG 2011;4 (5):558-565 [PubMed]
Biegstraaten M. Neurological aspects of Gaucher and Fabry disease. s.l.: s.n.; 2011. 189p. ISBN 9789490371791 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Schaik IN, Hollak CEM; copromotor(s): Aerts JMFG)
Biegstraaten M, van Schaik IN, Aerts JMFG, Langeveld M, Mannens MMAM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak CEM, A monozygotic twin pair with highly discordant Gaucher phenotypes. BLOOD CELL MOL DIS 2011;46 (1):39-41 [PubMed]
Bouwman MG, Rombach SM, Linthorst GE, Poorthuis BJHM, Deprez RHL, Aerts JMFG, Wijburg FA, Early cerebral manifestations in a young female with Fabry disease with skewed X-inactivation. CLIN GENET 2011;80 (5):500-502 [PubMed]
Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JEM, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM, Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. BLOOD 2011;118 (16):e118-e127 [PubMed]
Dekker N, Voorn-Brouwer T, Verhoek M, Wennekes T, Narayan RS, Speijer D, Hollak CEM, Overkleeft HS, Boot RG, Aerts JMFG, The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation. BLOOD CELL MOL DIS 2011;46 (1):19-26 [PubMed]
Duivenvoorden BA. Synthesis & biological applications of glycosylated iminosugars. s.l.: s.n.; 2011. 113p. ISBN 9789090264783 Proefschrift Universiteit van Leiden, Bio-organische Synthese (BioSyn). (Promotor(s): Overkleeft HS, Aerts JMFG; copromotor(s): Codeé JC)
Ghisaidoobe A, Bikker P, de Bruijn ACJ, Godschalk FD, Rogaar E, Guijt MC, Hagens P, Halma JM, van't Hart SM, Luitjens SB, van Rixel VHS, Wijzenbroek M, Zweegers T, Donker-Koopman WE, Strijland A, Boot R, van der Marel G, Overkleeft HS, Aerts JMFG, van den Berg RJBHN, Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars. ACS MED CHEM LETT 2011;2 (2):119-123 [PubMed]
Gold H, Boot RG, Aerts JMFG, Overkleeft HS, Codee JDC, van der Marel GA, A Concise Synthesis of Globotriaosylsphingosine. EUR J ORG CHEM 2011;2011 (9):1652-1663
Gold H, Munneke S, Dinkelaar J, Overkleeft HS, Aerts JMFG, Codée JDC, van der Marel GA, A practical synthesis of capped 4-methylumbelliferyl hyaluronan disaccharides and tetrasaccharides as potential hyaluronidase substrates. CARBOHYD RES 2011;346 (12):1467-1478 [PubMed]
Groener JE, Serlie MJ, Poppema A, Mirzaian M, Aerts JM, Ceramide in lipid emulsions used in parenteral nutrition: an innocent bystander?. JPEN-PARENTER ENTER 2011;35 (2):270-271 [PubMed]
Hollak CEM, Aerts JMFG, Aymé S, Manuel J, Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. ORPHANET J RARE DIS 2011;6 (1):16 [PubMed]
Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, Stroes ESG, Aerts JM, Kastelein JJP, Motazacker MM, Dallinga-Thie GM, Levels JHM, Zwinderman AH, Seidman JG, Seidman CE, Ljunggren S, Lefeber DJ, Morava E, Wevers RA, Fritz TA, Tabak LA, Lindahl M, Hovingh GK, Kuivenhoven JA, Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. CELL METAB 2011;14 (6):811-818 [PubMed]
Linthorst GE, Aerts JMFG, Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al. J INHERIT METAB DIS 2011;34 (1):237-238 [PubMed]
Smid BE, Aerts JMFG, Boot RG, Linthorst GE, Hollak CEM, Pharmacological small molecules for the treatment of lysosomal storage disorders (vol 19, pg 1367, 2010). EXPERT OPIN INV DRUG 2011;20 (2):309
Smid BE, Rombach SM, Aerts JMFG, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJHM, Hollak CEM, Groener JEM, Linthorst GE, Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. ORPHANET J RARE DIS 2011;6 (1):69 [PubMed]
Timmers S, de Vogel-van den Bosch J, Hesselink MKC, van Beurden D, Schaart G, Ferraz MJ, Losen M, Martinez-Martinez P, de Baets MH, Aerts JMFG, Schrauwen P, Paradoxical Increase in TAG and DAG Content Parallel the Insulin Sensitizing Effect of Unilateral DGAT1 Overexpression in Rat Skeletal Muscle. PLOS ONE 2011;6 (1):e14503 [PubMed]
van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE, Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. BBA-MOL BASIS DIS 2011;1812 (1):70-76 [PubMed]
van den Berg RJBHN, van den Elst H, Korevaar CGN, Aerts JMFG, van der Marel GA, Overkleeft HS, A Rapid and Efficient Synthesis of D-erythro-Sphingosine from D-ribo-Phytosphingosine. EUR J ORG CHEM 2011;2011 (33):6685-6689
van den Berg RJBHN, Wennekes T, Ghisaidoobe A, Donker-Koopman WE, Strijland A, Boot RG, van der Marel GA, Aerts JMFG, Overkleeft HS, Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors. ACS MED CHEM LETT 2011;2 (7):519-522 [PubMed]
van Dussen L, Lips P, Everts VE, Bravenboer N, Jansen IDC, Groener JEM, Maas M, Blokland JAK, Aerts JMFG, Hollak CEM, Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J CLIN ENDOCR METAB 2011;96 (7):2194-2205 [PubMed]
Witte MD, van der Marel GA, Aerts JMFG, Overkleeft HS, Irreversible inhibitors and activity-based probes as research tools in chemical glycobiology. ORG BIOMOL CHEM 2011;9 (17):5908-5926 [PubMed]
Witte MD, Walvoort MTC, Li KY, Kallemeijn WW, Donker-Koopman WE, Boot RG, Aerts JMFG, Codée JDC, van der Marel GA, Overkleeft HS, Activity-Based Profiling of Retaining β-Glucosidases: A Comparative Study. CHEMBIOCHEM 2011;12 (8):1263-1269 [PubMed]
Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS. Glycosphingolipids and insulin resistance in: Cowart A, editor. Sphingolipids and Metabolic Disease. S.l.: Landes Bioscience and Springer Science; 2010., p. 20-41
Aerts JMFG. Biomarkers for Fabry Disease in: Elstein D, Beck M, Altarescu G, editors. Fabry disease. New York: Springer Verlag; 2010., p. 133-152
Aerts JMFG, Yasothan U, Kirkpatrick P, Velaglucerase alfa. NAT REV DRUG DISCOV 2010;9 (11):837-838 [PubMed]
Bietrix F, Lombardo E, van Roomen CPAA, Ottenhoff R, Vos M, Rensen PCN, Verhoeven AJ, Aerts JM, Groen AK, Inhibition of Glycosphingolipid Synthesis Induces a Profound Reduction of Plasma Cholesterol and Inhibits Atherosclerosis Development in APOE*3 Leiden and Low-Density Lipoprotein Receptor-/- Mice. ARTERIOSCL THROM VAS 2010;30 (5):931-937 [PubMed]
Boomsma JMF, van Dussen L, Wiersma MG, Groener JEM, Aerts JMFG, Maas M, Hollak CEM, Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. BLOOD CELL MOL DIS 2010;44 (3):181-187 [PubMed]
Boot RG, Hollak CEM, Verhoek M, Alberts C, Jonkers RE, Aerts JM, Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. CLIN CHIM ACTA 2010;411 (1-2):31-36 [PubMed]
Bouwman MG, Rombach SM, Linthorst GE, Hollak CEM, Aerts JMFG, Wijburg FA, Hevige pijnklachten aan handen en voeten bij koorts en huidafwijkingen: de ziekte van Fabry. TIJDSCHR KINDERGENEESKD 2010;78 (2):69-73
Cox-Brinkman J, van den Bergh Weerman MA, Wijburg FA, Aerts JMFG, Florquin S, van der Lee JH, Hollak CEM, Ultrastructural Analysis of Dermal Fibroblasts in Mucopolysaccharidosis Type I: Effects of Enzyme Replacement Therapy and Hematopoietic Cell Transplantation. ULTRASTRUCT PATHOL 2010;34 (3):126-132 [PubMed]
de Ru MH, Wijburg FA, Aerts JMFG, Post EDM, Hollak CEM, Anemie, trombocytopenie en hepatosplenomegalie: de ziekte van Gaucher. TIJDSCHR KINDERGENEESKD 2010;78 (2):73-77
Dinkelaar J, Duivenvoorden BA, Wennekes T, Overkleeft HS, Boot RG, Aerts JMFG, Codée JDC, van der Marel GA, A Preparative Synthesis of Human Chitinase Fluorogenic Substrate (4prime-Deoxychitobiosyl)-4-methylumbelliferone. EUR J ORG CHEM 2010;2010 (13):2565-2570
Hollak CEM, Aerts JMFG, Belmatoug N, Bembi B, Bodamer O, Cappellini D, Collin-Histed T, Cox TM, Deegan P, Giraldo P, Hughes D, Lukina E, Manuel J, Michelakakis H, Di Rocco M, Vellodi A, Zimran A, Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease. BLOOD CELL MOL DIS 2010;44 (2):86-87 [PubMed]
Hollak CEM, vom Dahl S, Aerts JMFG, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, Di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM, Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. BLOOD CELL MOL DIS 2010;44 (1):41-47 [PubMed]
Hůlková H, Poupětová H, Harzer K, Mistry P, Aerts JMFG, Elleder M, Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries. J INHERIT METAB DIS 2010;33 (1):69-78 [PubMed]
Jennemann R, Rothermel U, Wang S, Sandhoff R, Kaden S, Out R, van Berkel TJ, Aerts JM, Ghauharali K, Sticht C, Gröne HJ, Hepatic Glycosphingolipid Deficiency and Liver Function in Mice. HEPATOLOGY 2010;51 (5):1799-1809 [PubMed]
Linthorst GE, Bouwman MG, Wijburg FA, Aerts JMFG, Poorthuis BJHM, Hollak CEM, Screening for Fabry disease in high-risk populations: a systematic review. J MED GENET 2010;47 (4):217-222 [PubMed]
Overkleeft H, Aerts H, Chemical biology of glucosylceramide metabolism in man. NPC HIGHLIGHTS 2010;2 (12):22-25
Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, van den Bergh Weerman MA, Groener JEM, Poorthuis BJ, Hollak CEM, Aerts JMFG, Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. BBA-MOL BASIS DIS 2010;1802 (9):741-748 [PubMed]
Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM, Vasculopathy in patients with Fabry disease: Current controversies and research directions. MOL GENET METAB 2010;99 (2):99-108 [PubMed]
Smid BE, Aerts JMFG, Boot RG, Linthorst GE, Hollak CEM, Pharmacological small molecules for the treatment of lysosomal storage disorders. EXPERT OPIN INV DRUG 2010;19 (11):1367-1379 [PubMed]
van den Nieuwendijk AMCH, Ruben M, Engelsma SE, Risseeuw MDP, van den Berg RJBHN, Boot RG, Aerts JM, Brussee J, van der Marel GA, Overkleeft HS, Synthesis of L-altro-1-Deoxynojirimycin, D-allo-1-Deoxynojirimycin, and D-galacto-1-Deoxynojirimycin from a Single Chiral Cyanohydrin. ORG LETT 2010;12 (17):3957-3959 [PubMed]
van Eijk M, Aust G, Brouwer MSM, van Meurs M, Voerman JSA, Dijke IE, Pouwels W, Sändig I, Wandel E, Aerts JMFG, Boot RG, Laman JD, Hamann J, Differential expression of the EGF-TM7 family members CD97 and EMR2 in lipid-laden macrophages in atherosclerosis, multiple sclerosis and Gaucher disease. IMMUNOL LETT 2010;129 (2):64-71 [PubMed]
van Eijk M, Voorn-Brouwer T, Scheij SS, Verhoeven AJ, Boot RG, Aerts JMFG, Curdlan-mediated regulation of human phagocyte-specific chitotriosidase. FEBS LETT 2010;584 (14):3165-3169 [PubMed]
van Scherpenzeel M, van den Berg RJBHN, Donker-Koopman WE, Liskamp RMJ, Aerts JMFG, Overkleeft HS, Pieters RJ, Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. BIOORGAN MED CHEM 2010;18 (1):267-273 [PubMed]
Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, van Eijk M, Ottenhoff R, Bijl N, Ghauharali K, Song H, O'Shea TJ, Liu H, Yew N, Copeland D, van den Berg RJ, van der Marel GA, Overkleeft HS, Aerts JM, Dual-Action Lipophilic Iminosugar Improves Glycemic Control in Obese Rodents by Reduction of Visceral Glycosphingolipids and Buffering of Carbohydrate Assimilation. J MED CHEM 2010;53 (2):689-698 [PubMed]
Wennekes T, van den Berg RJBHN, Boltje TJ, Donker-Koopman WE, Kuijper B, van der Marel GA, Strijland A, Verhagen CP, Aerts JMFG, Overkleeft HS, Synthesis and Evaluation of Lipophilic Aza-C-glycosides as Inhibitors of Glucosylceramide Metabolism. EUR J ORG CHEM 2010;2010 (7):1258-1283
Witte MD, Kallemeijn WW, Aten J, Li KY, Strijland A, Donker-Koopman WE, van den Nieuwendijk AMCH, Bleijlevens B, Kramer G, Florea BI, Hooibrink B, Hollak CEM, Ottenhoff R, Boot RG, van der Marel GA, Overkleeft HS, Aerts JMFG, Ultrasensitive in situ visualization of active glucocerebrosidase molecules. NAT CHEM BIOL 2010;6 (12):907-913 [PubMed]
Aerts JM, Boot RG. The Gaucher cell and chitotriosidase, the phagocyte chitinase in: Musumeci S, Paoletti MG, editors. Binomium Chitin-Chitinase. Hauppauge, NY 11788-3619, U.S.A.: Nova Science Publishers; 2009., p. 113-128
Bijl N. The role of glycosphingolipids in insulin signaling and lipid metabolism. S.L.: s.n.; 2009. 199p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, Groen AK; copromotor(s): Boot RG)
Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CPAA, Claessen N, Boot RG, Aten J, Groen AK, Aerts JMFG, van Eijk M, Modulation of Glycosphingolipid Metabolism Significantly Improves Hepatic Insulin Sensitivity and Reverses Hepatic Steatosis in Mice. HEPATOLOGY 2009;50 (5):1431-1441 [PubMed]
Bijl N, van Roomen CPAA, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK, Reduction of Glycosphingolipid Biosynthesis Stimulates Biliary Lipid Secretion In Mice. HEPATOLOGY 2009;49 (2):637-645 [PubMed]
Boot RG, Speijer D, Bussink AP, Aerts JMFG. The origin and genetics of human chitinases in: Musumeci S, Paoletti MG, editors. Binomium Chitin-Chitinase. Hauppauge, NY 11788-3619, U.S.A.: Nova Science Publishers; 2009., p. 77-99
Boot RG, van Breemen MJ, Wegdam W, Sprenger RR, de Jong S, Speijer D, Hollak CEM, van Dussen L, Hoefsloot HCJ, Smilde AK, de Koster CG, Vissers JPC, Aerts JMFG, Gaucher disease: a model disorder for biomarker discovery. EXPERT REV PROTEOMIC 2009;6 (4):411-419 [PubMed]
Bussink AP. Origin and features of mammalian chitinases. s.l.: s.n.; 2009. 291p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Boot R)
Bussink AP, Verhoek M, Vreede J, Ghauharali-van der Vlugt K, Donker-Koopman WE, Sprenger RR, Hollak CE, Aerts JMFG, Boot RG, Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J 2009;276 (19):5678-5688 [PubMed]
de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E, Mannens MM, Bikker H, Aerts JMFG, Kastelein JJP, Hollak CEM, Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. ATHEROSCLEROSIS 2009;204 (1):267-272 [PubMed]
Ghauharali-van der Vlugt K, Bussink AP, Groener JEM, Boot RG, Aerts JMFG, Detection of chitinase activity by 2-aminobenzoic acid labeling of chito-oligosaccharides. ANAL BIOCHEM 2009;384 (1):191-193 [PubMed]
Hollak CEM, de Fost M, van Dussen L, vom Dahl S, Aerts JMFG, Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. EXPERT OPIN PHARMACO 2009;10 (16):2641-2652 [PubMed]
Iyer A, van Eijk M, Silva E, Hatta M, Faber W, Aerts JMFG, Das PK, Increased chitotriosidase activity in serum of leprosy patients: Association with bacillary leprosy. CLIN IMMUNOL 2009;131 (3):501-509 [PubMed]
Langeveld M. Studies on the role of glycosphingolipids in metabolism. s.l.: s.n.; 2009. 204p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, Hollak CEM; copromotor(s): )
Langeveld M, Aerts JMFG, Glycosphingolipids and insulin resistance. PROG LIPID RES 2009;48 (3-4):196-205 [PubMed]
Risseeuw MDP, van den Berg RJBHN, Donker-Koopman WE, van der Marel GA, Aerts JMFG, Overhand M, Overkleeft HS, Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors. BIOORG MED CHEM LETT 2009;19 (23):6600-6603 [PubMed]
Soeters MR, Lammers NM, Dubbelhuis PF, Ackermans MT, Jonkers-Schuitema CF, Fliers E, Sauerwein HP, Aerts JM, Serlie MJ, Intermittent fasting does not affect whole-body glucose, lipid, or protein metabolism. AM J CLIN NUTR 2009;90 (5):1244-1251 [PubMed]
Strijbis K. Compartmentalization of metabolic pathways in Candida albicans: a matter of transport. s.l.: s.n.; 2009. 187p. ISBN 9789081406215 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Distel B)
van Breemen MJ, de Fost M, Maas M, Wiersma MG, Hollak CEM, Poll LW, vom Dahl S, Boot RG, Aerts JMFG, Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy. J INHERIT METAB DIS 2009;32 (2):274-279 [PubMed]
van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CPAA, Dubbelhuis PF, Seeman I, Ghauharali-van der Vlugt K, Overkleeft HS, Arbeeny C, Groen AK, Aerts JMFG, Reducing Glycosphingolipid Content in Adipose Tissue of Obese Mice Restores Insulin Sensitivity, Adipogenesis and Reduces Inflammation. PLOS ONE 2009;4 (3):e4723 [PubMed]
van Munster BC, van Breemen MJ, Moerland PD, Speijer D, de Rooij SE, Pfrommer CJ, Levi M, Hollmann MW, Aerts JM, Zwinderman AH, Korevaar JC, Proteomic Profiling of Plasma and Serum in Elderly Patients With Delirium. J NEUROPSYCH CLIN N 2009;21 (3):284-291 [PubMed]
Vedder AC, Biró E, Aerts JMFG, Nieuwland R, Sturk G, Hollak CEM, Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. NEPHROL DIAL TRANSPL 2009;24 (10):3074-3081 [PubMed]
Wegdam W, Moerland PD, Buist MR, Ver Loren van Themaat E, Bleijlevens B, Hoefsloot HCJ, de Koster CG, Aerts JMFG, Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets. PROTEOME SCI 2009;7 (1):19-(17 p) [PubMed]
Wennekes T, van den Berg RJBHN, Bonger KM, Donker-Koopman WE, Ghisaidoobe A, van der Marel GA, Strijland A, Aerts JMFG, Overkleeft HS, Synthesis and evaluation of dimeric lipophilic iminosugars as inhibitors of glucosylceramide metabolism. TETRAHEDRON-ASYMMETR 2009;20 (6-8):836-846
Wennekes T, van den Berg RJBHN, Boot RG, van der Marel GA, Overkleeft HS, Aerts JMFG, Glycosphingolipids-Nature, Function, and Pharmacological Modulation. ANGEW CHEM INT EDIT 2009;48 (47):8848-8869 [PubMed]
Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, Pacheco J, Piepenhagen P, Copeland D, Arbeeny C, Shayman JA, Aerts JM, Jiang C, Cheng SH, Yew NS, Inhibiting Glycosphingolipid Synthesis Ameliorates Hepatic Steatosis in Obese Mice. HEPATOLOGY 2009;50 (1):85-93 [PubMed]
Aerts J, Beck M, Martin R, Scarpa M, Seventh International Symposium on Lysosomal Storage Diseases. ACTA PAEDIATR 2008;97 (Suppl. 457):1-2 [PubMed]
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ, Elevated globotriaosylsphingosine is a hallmark of Fabry disease. P NATL ACAD SCI USA 2008;105 (8):2812-2817 [PubMed]
Aerts JM, van Breemen MJ, Bussink AP, Ghauharali K, Sprenger R, Boot RG, Groener JE, Hollak CE, Maas M, Smit S, Hoefsloot HC, Smilde AK, Vissers JP, de Jong S, Speijer D, de Koster CG, Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. ACTA PAEDIATR 2008;97 (Suppl. 457):7-14 [PubMed]
Biegstraaten M, van Schaik IN, Aerts JMFG, Hollak CEM, 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J INHERIT METAB DIS 2008;31 (3):337-349 [PubMed]
Bijl N, Scheij S, Houten S, Boot RG, Groen AK, Aerts JMFG, The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. J PHARMACOL EXP THER 2008;326 (3):849-855 [PubMed]
Bleijlevens B, van Breemen MJ, Donker-Koopman WE, de Koster CG, Aerts JMFG, Detection of mutant protein in complex biological samples: glucocerebrosidase mutations in Gaucher's disease. ANAL BIOCHEM 2008;372 (1):52-61 [PubMed]
Brinkman J. Lysosomal storage disorders in childhood. Efficacy and timing of emerging therapies. s.l.: s.n.; 2008. 208p. ISBN 9789090230641 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Wijburg FA, Aerts JMFG; copromotor(s): Hollak CEM)
Bussink AP, Vreede J, Aerts JMFG, Boot RG, A single histidine residue modulates enzymatic activity in acidic mammalian chitinase. FEBS LETT 2008;582 (6):931-935 [PubMed]
Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CEM, Wijburg FA, Aerts JMFG, Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J INHERIT METAB DIS 2008;31 (6):745-752 [PubMed]
Cox TM, Aerts JMFG, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CEM, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N, Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J INHERIT METAB DIS 2008;31 (3):319-336 [PubMed]
de Fost M. Gaucher disease type 1; associated morbidities and long term efficcacy of enzyme replacement therapy. s.l.: s.n.; 2008. 196p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, van Oers MHJ; copromotor(s): Hollak CEM)
de Fost M, Out TA, de Wilde FA, Tjin EPM, Pals ST, van Oers MHJ, Boot RG, Aerts JFMG, Maas M, vom Dahl S, Hollak CEM, Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. ANN HEMATOL 2008;87 (6):439-449 [PubMed]
de Fost M, van Noesel CJM, Aerts JMFG, Maas M, Pöll RG, Hollak CEM, Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. HAEMATOLOGICA 2008;93 (7):1119-1120 [PubMed]
Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CEM, Aerts JM, Groener JEM, Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. CLIN CHIM ACTA 2008;389 (1-2):109-113 [PubMed]
Groener JEM, Poorthuis BJHM, Kuiper S, Hollak CEM, Aerts JMFG, Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. BBA-MOL CELL BIOL L 2008;1781 (1-2):72-78 [PubMed]
Hollak CEM, Vedder AC, Winchester B, Aerts JMFG, Breunig F, Enzyme replacement therapy in Fabry disease: Towards a better understanding of the implications of antibody formation and dose. MOL GENET METAB 2008;95 (4):239-240 [PubMed]
Langeveld M, de Fost M, Aerts JMFG, Sauerwein HP, Hollak CEM, Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. BLOOD CELL MOL DIS 2008;40 (3):428-432 [PubMed]
Langeveld M, Ghauharali KJM, Sauerwein HP, Ackermans MT, Groener JEM, Hollak CEM, Aerts JM, Serlie MJ, Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J CLIN ENDOCR METAB 2008;93 (3):845-851 [PubMed]
Poorthuis BJHM, Aerts JMFG. Glycosphingolipids in: Blau N, Duran M, Gibson MK, editors. Laboratory Guide to the Methods in Biochemical Genetics. S.l.: Springer; 2008., p. 351-379
Soeters MR, Sauerwein HP, Dubbelhuis PF, Groener JE, Ackermans MT, Fliers E, Aerts JM, Serlie MJ, Muscle adaptation to short-term fasting in healthy lean humans. J CLIN ENDOCR METAB 2008;93 (7):2900-2903 [PubMed]
van Breemen MJ. Detection of biomarkers for lysosomal storage disorders using novel technologies. s.l.: s.n.; 2008. 248p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): )
van Breemen MJ, Aerts JMFG, Sprenger RR, Speijer D, Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities. CLIN CHIM ACTA 2008;396 (1-2):26-32 [PubMed]
Vedder AC. Fabry disease. Challenges in relation to optimization of enzyme replacement therapy. s.l.: s.n.; 2008. 192p. ISBN 9789090226637 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, ten Berge RJM; copromotor(s): Hollak CEM)
Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, ten Berge IJM, Groener JEM, Aerts JMFG, Wanner C, Hollak CEM, Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. MOL GENET METAB 2008;94 (3):319-325 [PubMed]
Vos A. Biosynthesis of cell wall α-glucan in fission yeast. s.l.: s.n.; 2008. 214p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Hochstenbach FMH)
Wennekes T. Lipophilic Iminosugars; Synthesis and Evaluation as Inhibitors of Glucosylceramide Metabolism. s.l.: s.n.; 2008. 319p. Proefschrift Universiteit Leiden, Leids Instituut voor Chemisch Onderzoek (LIC), Bio-organische synthese. (Promotor(s): Aerts JMFG, Overkleeft HS; copromotor(s): )
Wennekes T, Lang B, Leeman M, van der Marel GA, Smits E, Weber M, van Wiltenburg J, Wolberg M, Aerts JMFG, Overkleeft HS, Large-scale synthesis of the glucosylceramide synthase inhibitor N[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin. ORG PROCESS RES DEV 2008;12 (3):414-423
Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS, Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. DIABETES 2007;56 (5):1341-1349 [PubMed]
Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JMFG, Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J BIOL CHEM 2007;282 (2):1305-1312 [PubMed]
Bussink AP, Speijer D, Aerts JMFG, Boot RG, Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. GENETICS 2007;177 (2):959-970 [PubMed]
Bussink AP, van Swieten PF, Ghauharali K, Scheij S, van Eijk M, Wennekes T, van der Marel GA, Boot RG, Aerts JMFG, Overkleeft HS, N-azidoacetylmannosamine-mediated chemical tagging of gangliosides. J LIPID RES 2007;48 (6):1417-1421 [PubMed]
Cox-Brinkman J, Timmermans RGM, Wijburg FA, Donker WE, van de Ploeg AT, Aerts JMFG, Hollak CEM, Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J INHERIT METAB DIS 2007;30 (6):984 [PubMed]
Cox TM, Platt FM, Aerts JMFG. Medicinal use of iminosugars in: Compain P, Martin OR, editors. Iminosugars: From synthesis to therapeutic applications. Chicester, West Sussex PO19 8SQ: John Wiley & Sons Ltd.; 2007., p. 295-326
de Fost M, Aerts JMFG, Groener JEM, Maas M, Akkerman EM, Wiersma MG, Hollak CEM, Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. HAEMATOLOGICA 2007;92 (2):215-221 [PubMed]
Dekker N. Cellular roles of fungal (1,3)-alpha-glucanases. s.l.: s.n.; 2007. 208p. ISBN --- [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Hochstenbach F)
Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JFMG, van Weely S, Zimran A, Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. BLOOD 2007;110 (7):2296-2301 [PubMed]
Groener JEM, Poorthuis BJHM, Kuiper S, Helmond MTJ, Hollak CEM, Aerts JMFG, HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. CLIN CHEM 2007;53 (4):742-747 [PubMed]
Hendriks MMWB, Smit S, Akkermans WLMW, Reijmers TH, Eilers PHC, Hoefsloot HCJ, Rubingh CM, de Koster CG, Aerts JM, Smilde AK, How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics. PROTEOMICS 2007;7 (20):3672-3680 [PubMed]
Hollak CEM, Aerts JMFG. Diagnosis and Laboratory Features in: Futerman AH, Zimran A, editors. Gaucher Disease. Boca Raton: CRC Press; 2007., p. 249-289
Hollak CEM, de Fost M, Aerts JMFG, vom Dahl S, Low-dose versus high-dose therapy for Gaucher disease: Goals and markers. BLOOD 2007;109 (1):387; author reply 387-387; author reply 388 [PubMed]
Hollak CEM, Vedder AC, Linthorst GE, Aerts JMFG, Novel therapeutic targets for the treatment of Fabry disease. EXPERT OPIN THER TAR 2007;11 (6):821-833 [PubMed]
Langeveld M, Endert E, Wiersinga WM, Aerts JMFG, Hollak CEM, Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J INHERIT METAB DIS 2007;30 (6):985 [PubMed]
Langeveld M, Scheij S, Dubbelhuis P, Hollak CEM, Sauerwein HP, Simons P, Aerts JMFG, Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. METABOLISM 2007;56 (3):314-319 [PubMed]
Levels JHM, Bleijlevens B, Rezaee F, Aerts JMFG, Meijers JCM, SELDI-TOF mass spectrometry of high-density lipoprotein. PROTEOME SCI 2007;5 (1):15 [PubMed]
McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JMFG, Cheng SH, Copeland DP, Marshall J, A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. MOL GENET METAB 2007;91 (3):259-267 [PubMed]
Piekarska K. The role of peroxisomal metabolism in virulence of Candida albicans. s.l.: s.n.; 2007. 164p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Distel B)
Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CEM, Groener JE, Aerts JMFG, Monitoring of Gaucher patients with a novel chitotriosidase assay. CLIN CHIM ACTA 2007;381 (2):136-139 [PubMed]
Serlie MJ, Allick G, Groener JE, Ackermans MT, Heijligenberg R, Voermans BC, Aerts JM, Meijer AJ, Sauerwein HP, Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. J CLIN ENDOCR METAB 2007;92 (1):166-171 [PubMed]
Serlie MJ, Meijer AJ, Groener JE, Duran M, Endert E, Fliers E, Aerts JM, Sauerwein HP, Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects. J CLIN ENDOCR METAB 2007;92 (4):1524-1529 [PubMed]
Simons PJ, van den Pangaart PS, Aerts JMFG, Boon L, Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J ENDOCRINOL 2007;192 (2):289-299 [PubMed]
Smit S, van Breemen MJ, Hoefsloot HCJ, Smilde AK, Aerts JMFG, de Koster CG, Assessing the statistical validity of proteomics based biomarkers. ANAL CHIM ACTA 2007;592 (2):210-217 [PubMed]
Soeters MR, Sauerwein HP, Groener JE, Aerts JM, Ackermans MT, Glatz JFC, Fliers E, Serlie MJ, Gender-related differences in the metabolic response to fasting. J CLIN ENDOCR METAB 2007;92 (9):3646-3652 [PubMed]
van Breemen MJ, de Fost M, Voerman JSA, Laman JD, Boot RG, Maas M, Hollak CEM, Aerts JM, Rezaee F, Increased plasma macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta levels in type 1 Gaucher disease. BBA-MOL BASIS DIS 2007;1772 (7):788-796 [PubMed]
van Eijk M, Scheij SS, van Roomen CPAA, Speijer D, Boot RG, Aerts JMFG, TLR- and NOD2-dependent regulation of human phagocyte-specific chitotriosidase. FEBS LETT 2007;581 (28):5389-5395 [PubMed]
Vedder AC, Gerdes VEA, Poorthuis BJHM, Helmond M, Trip MD, Aerts JMFG, Hollak CEM, Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males. J INHERIT METAB DIS 2007;30 (6):988 [PubMed]
Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, Bouma BJ, Aerts JMFG, Hirth A, Hollak CEM, Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLOS ONE 2007;2 (7):e598 [PubMed]
Vedder AC, Linthorst GE, van Breemen MJ, Groener JEM, Bemelman FJ, Strijland A, Mannens MMAM, Aerts JMFG, Hollak CEM, The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J INHERIT METAB DIS 2007;30 (1):68-78 [PubMed]
Vissers JPC, Langridge JI, Aerts JMFG, Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. MOL CELL PROTEOMICS 2007;6 (5):755-766 [PubMed]
Wennekes T, van den Berg RJBHN, Donker W, van der Marel GA, Strijland A, Aerts JMFG, Overkleeft HS, Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J ORG CHEM 2007;72 (4):1088-1097 [PubMed]
Williams CP. Pex5p and ubiquitin: regulation of the PTS1 protein import receptor. s.l.: s.n.; 2007. 168p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Distel B)
Aerts JMFG, Hollak CEM, Boot RG, Groener JEM, Maas M, Substrate reduction therapy of glycosphingolipid storage disorders. J INHERIT METAB DIS 2006;29 (2-3):449-456 [PubMed]
Boot RG, Verhoek M, Langeveld M, Renkema GH, Hollak CEM, Weening JJ, Donker-Koopman WE, Groener JE, Aerts JMFG, CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J INHERIT METAB DIS 2006;29 (4):564-571 [PubMed]
Boven LA, van Meurs M, van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD, Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. BRAIN 2006;129 (Part 2):517-526 [PubMed]
Bussink AP, van Eijk M, Renkema GH, Aerts JM. The biology of the Gaucher cell: the cradle of human chitinases in: Jeon KW, editor. International review of cytology. A survey of cell biology. Volume 252. Amsterdam: Academic Press Elsevier; 2006., p. 71-128
Bussink AP, van Eijk M, Renkema GH, Aerts JM, Boot RG, The biology of the Gaucher cell: the cradle of human chitinases. INT REV CYTOL 2006;252:71-128 [PubMed]
Cangar O, Aerts JM, Vranken E, Berckmans D, End-weight prediction in broiler growth. BRIT POULTRY SCI 2006;47 (3):330-335 [PubMed]
de Fost M, Hollak CEM, Groener JEM, Aerts JMFG, Maas M, Poll LW, Wiersma MG, Häussinger D, Brett S, Brill N, vom Dahl S, Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. BLOOD 2006;108 (3):830-835 [PubMed]
Hollak CEM, Aerts JMFG. Diagnosis and laboratory features in Gaucher disease in: Zimran A, Futerman T, editors. Gaucher disease. S.l.: s.n.; 2006.
Linthorst GE. Fabry disease revisted. Clinical and laboratory studies at the advent of enzyme supplementation therapy. S.l.: s.n.; 2006. 297p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, van Oers MHJ; copromotor(s): Hollak CEM)
Linthorst GE, Vedder AC, Ormel EE, Aerts JMFG, Hollak CEM, Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. NEPHROL DIAL TRANSPL 2006;21 (2):355-360 [PubMed]
Maas M, Hollak CEM, Akkerman EM, Aerts JFM, Radiology of Gaucher disease (type 1) and bone manifestations: the Dutch experience. JBR-BTR 2006;89 (6):318-321 [PubMed]
van Breemen MJ, Bleijlevens B, de Koster CG, Aerts JMFG, Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. BBA-PROTEINS PROTEOM 2006;1764 (10):1626-1632 [PubMed]
Vedder AC, Cox-Brinkman J, Hollak CEM, Linthorst GE, Groener JEM, Helmond MTJ, Scheij S, Aerts JMFG, Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. MOL GENET METAB 2006;89 (3):239-244 [PubMed]
Vedder AC, Strijland A, van den Bergh Weerman MA, Florquin S, Aerts JMFG, Hollak CEM, Manifestations of Fabry disease in placental tissue. J INHERIT METAB DIS 2006;29 (1):106-111 [PubMed]
Aerts JMFG, Hollak CEM, van Breemen M, Maas M, Groener JEM, Boot RG, Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. ACTA PAEDIATR 2005;94 (Suppl. 447):43-46; discussion 37-8 [PubMed]
Aerts JMFG, van Breemen MJ, Bussink AP, Brinkman J, Hollak CEM, Langeveld M, Linthorst GE, Vedder AC, de Fost M, The blood-brain barrier and treatment of lysosomal storage disease. INT CONGRESS SERIES 2005;1277:19-31
Boot RG, Bussink AP, Aerts JMFG, Human acidic mammalian chitinase erroneously known as eosinophil chemotactic cytokine is not the ortholog of mouse YM1. J IMMUNOL 2005;175 (4):2041-2042 [PubMed]
Boot RG, Bussink AP, Verhoek M, de Boer PAJ, Moorman AFM, Aerts JMFG, Marked differences in tissue-specific expression of chitinases in mouse and man. J HISTOCHEM CYTOCHEM 2005;53 (10):1283-1292 [PubMed]
Brinkman J, Wijburg FA, Hollak CE, Groener JE, Verhoek M, Scheij S, Aten J, Boot RG, Aerts JM, Plasma chitotriosidase and CCL18: Early biochemical surrogate markers in type B Niemann-Pick disease. J INHERIT METAB DIS 2005;28 (1):13-20 [PubMed]
Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JMFG, Cox TM, Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. BLOOD CELL MOL DIS 2005;35 (2):259-267 [PubMed]
Dimitriou E, Verhoek M, Altun S, Karabatsos F, Moraitou M, Youssef J, Boot R, Sarafidou J, Karagiorga M, Aerts H, Michelakakis H, Elevated plasma chemokine CCL18/PARC in beta-thalassemia. BLOOD CELL MOL DIS 2005;35 (3):328-331 [PubMed]
Hollak CEM, Boot RG, Poorthuis BJHM, Aerts JMFG, Van gen naar ziekte; de ziekte van Gaucher. NED TIJDSCHR GENEESKD 2005;149 (39):2163-2166 [PubMed]
Kragt A. Studies on the role of the Er and ubuquitin in peroxisomes biogenesis. S.l.: s.n.; 2005. 168p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Distel B)
Linthorst GE, Vedder AC, Aerts JMFG, Hollak CEM, Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. CLIN CHIM ACTA 2005;353 (1-2):201-203 [PubMed]
Lonser RR, Walbridge S, Murray GJ, Aizenberg MR, Vortmeyer AO, Aerts JMFG, Brady RO, Oldfield EH, Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. ANN NEUROL 2005;57 (4):542-548 [PubMed]
Rao FV, Houston DR, Boot RG, Aerts JMFG, Hodkinson M, Adams DJ, Shiomi K, Omura S, van Aalten DMF, Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. CHEM BIOL 2005;12 (1):65-76 [PubMed]
Schmitz M, Alfalah M, Aerts JMFG, Naim HY, Zimmer KP, Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease. INT J BIOCHEM CELL B 2005;37 (11):2310-2320 [PubMed]
Simons PJ, van den Pangaart PS, van Roomen CPAA, Aerts JMFG, Boon L, Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha- and interleukin-1beta-treated human preadipocytes are potent leptin producers. CYTOKINE 2005;32 (2):94-103 [PubMed]
Timmer MSM, Vinciano Chumillas M, Donker-Koopman WE, Aerts JMFG, van der Marel GA, Overkleeft HS, van Boom JH, Selective cross-metathesis of C-allyl-glycosides.. J CARBOHYD CHEM 2005;24 (4):335-351
van Eijk M, van Roomen CPAA, Renkema GH, Bussink AP, Andrews L, Blommaart EFC, Sugar A, Verhoeven AJ, Boot RG, Aerts JMFG, Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. INT IMMUNOL 2005;17 (11):1505-1512 [PubMed]
Boot RG, Verhoek M, de Fost M, Hollak CEM, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JMFG, Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. BLOOD 2004;103 (1):33-39 [PubMed]
Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD, Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. AM J CLIN PATHOL 2004;122 (3):359-369 [PubMed]
Dubbelhuis PF. Regulation of metabolism by amino acid dependant signal transduction. S.l.: s.n.; 2004. 160p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG; copromotor(s): Meijer AJ)
Elstein D, Hollak C, Aerts JMFG, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A, Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J INHERIT METAB DIS 2004;27 (6):757-766 [PubMed]
Linthorst GE, de Rie MA, Tjiam KH, Aerts JMFG, Dingemans KP, Hollak CEM, Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion. BRIT J DERMATOL 2004;150 (3):575-577 [PubMed]
Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG, Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. KIDNEY INT 2004;66 (4):1589-1595 [PubMed]
Møller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK, Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. EUR J HAEMATOL 2004;72 (2):135-139 [PubMed]
Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A, Therapeutic goals in the treatment of Gaucher disease. SEMIN HEMATOL 2004;41 (4 Suppl 5):4-14 [PubMed]
Shen C, Bullens D, Kasran A, Maerten P, Boon L, Aerts JMFG, van Assche G, Geboes K, Rutgeerts P, Ceuppens JL, Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. INT IMMUNOL 2004;4 (7):939-951 [PubMed]
van den Berg RJBHN, Donker-Koopman W, van Boom JH, Aerts HMFG, Noort D, Design and synthesis of 2-acetamidomethyl derivatives of isofagomine as potential inhibitors of human lysosomal beta-hexosaminidases. BIOORGAN MED CHEM 2004;12 (5):891-902 [PubMed]
Aerts JMFG, Hollak CEM, Boot RG, Groener A. Macrofages as therapeutic targets in lysosomal storage disorders in: Gordon S, editor. The macrophage as therapeutic target. Berlin Heidelberg: Springer; 2003., p. 193-208
Aerts JM, Hollak C, Boot R, Groener A, Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. PHILOS T R SOC B 2003;358 (1433):905-914 [PubMed]
Aguilera B, Ghauharali-van der Vlugt K, Helmond MTJ, Out JMM, Donker-Koopman WE, Groener JEM, Boot RG, Renkema GH, van der Marel GA, van Boom JH, Overkleeft HS, Aerts JMFG, Transglycosidase activity of chitotriosidase - Improved enzymatic assay for the human macrophage chitinase. J BIOL CHEM 2003;278 (42):40911-40916 [PubMed]
Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JMFG, Recombinant enzyme therapy for Fabry disease: Absence of editing of human alpha-galactosidase A mRNA. AM J HUM GENET 2003;72 (1):23-31 [PubMed]
Cox TM, Aerts JMFG, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Sá Miranda MC, Zimran A, The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement. J INHERIT METAB DIS 2003;26 (6):513-526 [PubMed]
de Fost M, Aerts JMFG, Hollak CEM, Gaucher disease: from fundamental research to effective therapeutic interventions. NETH J MED 2003;61 (1):3-8 [PubMed]
Groener JEM, Hollak CEM, Bakker HD, Boot RG, Aerts JMFG, Behandeling van patiénten met de ziekte van Gaucher aan de hand van chemische ziektemarkers. NED TIJDSCHR KLIN CHEM LABORATORIUMGENEESKD 2003;28:352-355
Linthorst GE, Folman CC, Aerts JMFG, Hollak CEM, Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency). BLOOD CELL MOL DIS 2003;31 (3):324-326 [PubMed]
Linthorst GE, Hollak CEM, Korevaar JC, van Manen JG, Aerts JMFG, Boeschoten EW, alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. NEPHROL DIAL TRANSPL 2003;18 (8):1581-1584 [PubMed]
Maas M, van Kuijk C, Stoker J, Hollak CEM, Akkerman EM, Aerts JFMG, den Heeten GJ, Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to dixon quantitative chemical shift MR imaging - Initial experience. RADIOLOGY 2003;229 (2):554-561 [PubMed]
Rao FV, Houston DR, Boot RG, Aerts JMFG, Sakuda S, van Aalten DMF, Crystal structures of allosamidin derivatives in complex with human macrophage chitinase. J BIOL CHEM 2003;278 (22):20110-20116 [PubMed]
Fusetti F, von Moeller H, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, Aerts JMFG, van Aalten DMF, Structure of human chitotriosidase - Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J BIOL CHEM 2002;277 (28):25537-25544 [PubMed]
Heitner R, Elstein D, Aerts J, Weely Sv, Zimran A, Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. BLOOD CELL MOL DIS 2002;28 (2):127-133 [PubMed]
Maas M, Hollak CEM, Akkerman EM, Aerts JMFG, Stoker J, den Heeten GJ, Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AM J ROENTGENOL 2002;179 (4):961-965 [PubMed]
Moller HJ, Aerts JMFG, Gronbaek H, Peterslund NA, Petersen PH, Hornung N, Rejnmark L, Jabbarpour E, Moestrup SK, Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. SCAND J CLIN LAB INV 2002;62 (Suppl. 237):29-34
Poll LW, Koch JA, Willers R, Aerts H, Scherer A, Häussinger D, Mödder U, vom Dahl S, Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. BLOOD CELL MOL DIS 2002;28 (2):209-220 [PubMed]
Aerts H, Beck M, Cox TM, Lysosomal storage diseases - Fabry disease: new insights and future perspectives.. J INHERIT METAB DIS 2001;24 (suppl 2):1-2
Baumann N, Lefèvre M, Turpin JC, Fontaine B, Hosseini H, Aerts H, van Weekly S, Atypical course of neuropathic Gaucher's disease: follow up from early infancy until adulthood. J NEUROL NEUROSUR PS 2001;70 (1):133-134 [PubMed]
Boot RG, Blommaart EF, Swart E, Ghauharali-van der Vlugt K, Bijl N, Moe C, Place A, Aerts JM, Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J BIOL CHEM 2001;276 (9):6770-6778 [PubMed]
Hollak CE, Maas M, Aerts JM, Clinically relevant therapeutic endpoints in type I Gaucher disease. J INHERIT METAB DIS 2001;24 (Suppl. 2):97-105; discussion 87-8 [PubMed]
Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H, Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. BLOOD CELL MOL DIS 2001;27 (6):1005-1012 [PubMed]
Linthorst GE, Hollak CEM, Heymans HSA, Aerts JMFG, De ziekte van Fabry: etiologie, kliniek en behandeling.. NED TIJDSCHR DERMATOL VENEREOL 2001;11:7-9
Moraitou M, van Weely S, Verhoek M, Aerts JMFG, Dimitriou E, Michelakakis H, The facile detection of 1505G-->A in Gaucher patients with different phenotypes. BBA-MOL BASIS DIS 2001;1536 (2-3):97-102 [PubMed]
Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, Cox TM, Lachmann RH, Hollak C, Aerts JM, van Weely S, Hrebícek M, Moyses C, Gow I, Elstein D, Zimran A, Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J INHERIT METAB DIS 2001;24 (2):275-290 [PubMed]
van Sluijters DA. Signal Transduction and Metabolism. Glucosylceramide and Ceramide. Amino acids and Insulin.. S.l.: s.n.; 2001. 147p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan EJ; copromotor(s): Aerts JMFG, Meijer AJ)
Bosman DK, van Weely S, Reversz T, de Koning T, Aerts JM, Bakker HD, De lange termijn effecten van enzym therapie bij de ziekte van Gaucher type 1 en 3.. TIJDSCHR KINDERGENEESKD 2000;68 (Suppl 1):13-13
Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. LANCET 2000;355 (9214):1481-1485 [PubMed]
Linthorst GE, Hollak CE, Bosman DK, Heymans HS, Aerts JM, De ziekte van Fabry: op weg naar een behandeling. NED TIJDSCHR GENEESKD 2000;144 (50):2391-2395 [PubMed]
Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, Pöll R, The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J INHERIT METAB DIS 2000;23 (1):77-82 [PubMed]
van Weely S, Aerts H, Glucosylceramide: synthesis and degradation. GAUCHER CLIN PERSPECT 2000;8:1079-2058
Aerts JMFG, Boot RG, Blommaart EFC, Renkema GH, van Weely S, Hollak CEM, Chitotriosidase: applications and features of the enzyme. GAUCHER CLIN PERSPECT 1999;7:4-8
Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ, Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. ARTERIOSCL THROM VAS 1999;19 (3):687-694 [PubMed]
Lauw FN, te Velde AA, Dekkers PE, Speelman P, Aerts JM, Hack CE, van Deventer SJ, van der Poll T, Activation of mononuclear cells by interleukin-12: an in vivo study in chimpanzees. J CLIN IMMUNOL 1999;19 (4):231-238 [PubMed]
van Sluijters DA, van Woerkom GM, Aerts JM, Meijer AJ, Sphingomyelinase treatment of rat hepatocytes inhibits cell-swelling-stimulated glycogen synthesis by causing cell shrinkage. EUR J BIOCHEM 1999;266 (2):653-659 [PubMed]
vom Dahl S, Harzer K, Rolfs A, Albrecht B, Niederau C, Vogt C, van Weely S, Aerts J, Müller G, Häussinger D, Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J HEPATOL 1999;31 (4):741-746 [PubMed]
Zimmer KP, le Coutre P, Aerts HM, Harzer K, Fukuda M, O'Brien JS, Naim HY, Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation). J PATHOL 1999;188 (4):407-414 [PubMed]
Aerts JMFG, van Gool WA. Inleiding over vouwziekten. in: Borst P, van Everdingen JEE, van Gool WA, editors. Vouwfouten. Prionziekten als model.. Amsterdam-Overveen: Boom-Belvedere; 1998., p. 26-40
Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM, The human chitotriosidase gene. Nature of inherited enzyme deficiency. J BIOL CHEM 1998;273 (40):25680-25685 [PubMed]
de Jong JG, Aerts JM, van Weely S, Hollak CE, van Pelt J, van Woerkom LM, Liebrand-van Sambeek ML, Wevers RA, Oligosaccharide excretion in adult Gaucher disease. J INHERIT METAB DIS 1998;21 (1):49-59 [PubMed]
Hollak CE, Aerts JM, van Oers MH, Alglucerase: practical guidance on appropriate dosage and administration in patients with Gaucher disease. BIODRUGS 1998;9 (1):11-23 [PubMed]
Labadaridis J, Dimitriou E, Costalos C, Aerts J, van Weely S, Donker-Koopman WE, Michelakakis H, Serial chitotriosidase activity estimations in neonatal systemic candidiasis. ACTA PAEDIATR 1998;87 (5):605 [PubMed]
Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, Strijland A, van der Burg AM, Koomen GJ, Pandit UK, Aerts JM, Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J BIOL CHEM 1998;273 (41):26522-26527 [PubMed]
Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM, Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. EUR J BIOCHEM 1998;251 (1-2):504-509 [PubMed]
van Royen-Kerkhof A, Poll-The BT, Kleijer WJ, van Diggelen OP, Aerts JM, Hopwood JJ, Beemer FA, Coexistence of Gaucher disease type 1 and Joubert syndrome. J MED GENET 1998;35 (11):965-966 [PubMed]
Aerts JM, Hollak CE, Plasma and metabolic abnormalities in Gaucher's disease. BAILLIERES CLIN HAEMATOL 1997;10 (4):691-709 [PubMed]
Boot RG. Gaucher Disease and Chitotriosidase. Biochemical Investigations.. S.l.: s.n.; 1997. 235p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Tabak HF; copromotor(s): Aerts JMFG)
Boot RG, Hollak CE, Verhoek M, Sloof P, Poorthuis BJ, Kleijer WJ, Wevers RA, van Oers MH, Mannens MM, Aerts JM, van Weely S, Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value. HUM MUTAT 1997;10 (5):348-358 [PubMed]
Hodanová K, Hrebícek M, Cervenková M, Aerts JM, Zeman J, Incorrect assignment of N370S mutation status by mismatched PCR/RFLP method in two Gaucher patients. J INHERIT METAB DIS 1997;20 (4):611-612 [PubMed]
Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH, Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. AM J MED 1997;103 (3):185-191 [PubMed]
Hollak CE, Evers L, Aerts JM, van Oers MH, Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. BLOOD CELL MOL DIS 1997;23 (2):201-212 [PubMed]
Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH, Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. BRIT J HAEMATOL 1997;96 (3):470-476 [PubMed]
Pasmanik-Chor M, Madar-Shapiro L, Stein EO, Aerts H, Gatt S, Horowitz M, Expression of mutated glucocerebrosidase alleles in human cells. HUM MOL GENET 1997;6 (6):887-895 [PubMed]
Renkema GH. Chitotriosidase. Studies on the human chitinase.. S.l.: s.n.; 1997. 192p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan EJ; copromotor(s): Aerts JMFG)
Renkema GH, Boot RG, Strijland A, Donker-Koopman WE, van den Berg M, Muijsers AO, Aerts JM, Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. EUR J BIOCHEM 1997;244 (2):279-285 [PubMed]
Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW, Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. ANN NEUROL 1997;42 (4):613-621 [PubMed]
Aerts JMFG, The European Working Group on Gaucher Disease. GAUCHER CLIN PERSPECT 1996;4:11-13
Aerts JMFG, Boot RG, Renkema GH, van Weely S, Hollak CEM, Donker-Koopman WE, Strijland A, Verhoek M. Chitotriosidase: a human macrophage chitinase that is a marker for Gaucher disease manifestation. in: Muzzarelli RAA, editors. Chitin Enzymology vol. 2. Ancona, Italy: Atec Edizioni; 1996., p. 3-10
Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM, Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. EUR J BIOCHEM 1996;237 (2):344-349 [PubMed]
Bosman DK, Hollak CE, Aerts JM, Bakker HD, The effect of enzyme therapy in a patient with Gaucher disease type III. J INHERIT METAB DIS 1996;19 (5):703-704 [PubMed]
Fernandez-Borja M, Verwoerd D, Sanderson F, Aerts H, Trowsdale J, Tulp A, Neefjes J, HLA-DM and MHC class II molecules co-distribute with peptidase-containing lysosomal subcompartments. INT IMMUNOL 1996;8 (5):625-640 [PubMed]
Hollak CEM. Gaucher Disease. Clinical and laboratory studies in relation to enzyme supplementation therapy.. S.l.: s.n.; 1996. 218p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Goudsmit R, von dem Borne AEGK; copromotor(s): van Oers MHJ, Aerts JMFG)
Hollak CE, van Oers MH, Maaswinkel P, Aerts JM, Goudsmit R, Behandeling van de ziekte van Gaucher in Nederland met enzymvervangingstherapie. NED TIJDSCHR GENEESKD 1996;140 (19):1011-1013 [PubMed]
Hrebícek M, Zeman J, Musilová J, Hodanová K, Renkema GH, Vepreková L, Ledvinová J, Hrebícek D, Sokolová J, Aerts JM, Elleder M, A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. VIRCHOWS ARCH 1996;429 (4-5):305-309 [PubMed]
Luiken JJ, Aerts JM, Meijer AJ, The role of the intralysosomal pH in the control of autophagic proteolytic flux in rat hepatocytes. EUR J BIOCHEM 1996;235 (3):564-573 [PubMed]
McCabe ERB, Fine BA, Golbus MS, Greenhouse JB, McGrath GC, New M, O'Brien WE, Prowley PT, Sly WS, Spence MA, Stockman III JA, Whyte M, Wilson W, Wolf B, Aerts JMFG, Barranger JA, Gaucher disease: current issues in diagnosis and treatment.. JAMA-J AM MED ASSOC 1996;275 (7):548-553
Michelakakis H, Spanou C, Kondyli A, Dimitriou E, van Weely S, Hollak CE, van Oers MH, Aerts JM, Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. BBA-MOL BASIS DIS 1996;1317 (3):219-222 [PubMed]
Mikhaylova M, Wiederschain G, Mikhaylov V, Aerts JM, The enzymatic hydrolysis of 6-acylamino-4-methylumbelliferyl-beta-D-glucosides: identification of a novel human acid beta-glucosidase. BBA-MOL BASIS DIS 1996;1317 (1):71-79 [PubMed]
Pasmanik-Chor M, Elroy-Stein O, Aerts H, Agmon V, Gatt S, Horowitz M, Overexpression of human glucocerebrosidase containing different-sized leaders. BIOCHEM J 1996;317 ( Pt 1):81-88 [PubMed]
Aerts JMFG, Boot RG, Renkema GH, van Weely S, Jones S, Hollak CEM, van Oers MHJ, Molecular and biochemical abnormalities of Gaucher disease. Chitotriosidase, a newly identified biochemical marker.. SEMIN HEMATOL 1995;32 (suppl. 1):10-13
Aerts JM, Goudsmit R, Tager JM, editors, Proceedings of the First Workshop of the European Working Group on Gaucher Disease.. Amsterdam: Drukkerij Universiteit van Amsterdam; 1995. 120p.
Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM, Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J BIOL CHEM 1995;270 (44):26252-26256 [PubMed]
Duursma SA, Aerts JMFG, Belmatoug N, Cox TM, Einhorn TA, Esplin JA, Hollak CEM, Incerti C, Pastores GM, Rademakers RP, Zaizov R, Management of Gaucher disease. Current status and future directions: A roundtable discussion.. SEMIN HEMATOL 1995;32 (suppl. 1):45-52
Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, Hollak CE, Aerts JM, Galjaard H, van Diggelen OP, Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J INHERIT METAB DIS 1995;18 (6):717-722 [PubMed]
Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH, Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. LANCET 1995;345 (8963):1474-1478 [PubMed]
Michelakakis H, Dimitriou E, van Weely S, Boot RG, Mavridou I, Verhoek M, Aerts JM, Characterization of glucocerebrosidase in Greek Gaucher disease patients: mutation analysis and biochemical studies. J INHERIT METAB DIS 1995;18 (5):609-615 [PubMed]
Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM, Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J BIOL CHEM 1995;270 (5):2198-2202 [PubMed]
Aerts JMFG, Biochemical markers of disease manifestation and therapeutic correction in sera of Gaucher patients. GAUCHER CLIN PERSPECT 1994;2:12-16
Hollak CE, van Weely S, van Oers MH, Aerts JM, Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J CLIN INVEST 1994;93 (3):1288-1292 [PubMed]
Lacerda L, Amaral O, Pinto R, Aerts J, Sá Miranda MC, The N370S mutation in the glucocerebrosidase gene of Portuguese type 1 Gaucher patients: linkage to the PvuII polymorphism. J INHERIT METAB DIS 1994;17 (1):85-88 [PubMed]
Lacerda L, Amaral O, Pinto R, Oliveira P, Aerts J, Sá Miranda MC, Gaucher disease: N370S glucocerebrosidase gene frequency in the Portuguese population. CLIN GENET 1994;45 (6):298-300 [PubMed]
Tager JM, Aerts JM, van den Bogert C, Wanders RJ, Signals on proteins, intracellular targeting and inborn errors of organellar metabolism. J INHERIT METAB DIS 1994;17 (4):459-469 [PubMed]
van Es HH, Renkema H, Aerts H, Schurr E, Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene. MOL BIOCHEM PARASIT 1994;68 (2):209-219 [PubMed]
Aerts JMFG, Schram AW. Posttranslational processing of proteins. in: Franks F, editor. Protein Biotechnology. New York: Plenum Press; 1993., p. 191-236
Aerts JM, van Weely S, Boot R, Hollak CE, Tager JM, Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J INHERIT METAB DIS 1993;16 (2):288-291 [PubMed]
Amaral O, Lacerda L, Santos R, Pinto RA, Aerts H, Sa Miranda MC, Type 1 Gaucher disease: molecular, biochemical, and clinical characterization of patients from northern Portugal. BIOCHEM MED METAB BIOL 1993;49 (1):97-107 [PubMed]
Hollak CE, Aerts JM, van Oers MH, Treatment of Gaucher's disease. NEW ENGL J MED 1993;328 (21):1565-6; author reply 1567 [PubMed]
Hollak CEM, Aerts JMFG, van Oers MHJ, Enzyme replacement therapy for type 1 Gaucher disease: experience with low-dose schedules of alglucerase. GAUCHER CLIN PERSPECT 1993;1:12-13
Lacerda L, Amaral O, Pinto R, Aerts J, Sá Miranda MC, Identification of Gaucher disease carriers: glucocerebrosidase antigen and DNA analysis. BIOCHEM MED METAB BIOL 1993;50 (2):190-196 [PubMed]
Smit NP, van Roermund CW, Aerts HM, Heikoop JC, van den Berg M, Pavel S, Wanders RJ, Subcellular fractionation of cultured normal human melanocytes: new insights into the relationship of melanosomes with lysosomes and peroxisomes. BBA-MOL BASIS DIS 1993;1181 (1):1-6 [PubMed]
Tager JM, Aerts JMFG, Evolution of enzyme augmentation therapy for Gaucher disease. GAUCHER CLIN PERSPECT 1993;1:2-4
van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM, Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. BBA-MOL BASIS DIS 1993;1181 (1):55-62 [PubMed]
van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM, Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J CLIN INVEST 1993;91 (3):1167-1175 [PubMed]
Schellens JPM, Meijer AJ, Aerts JMFG, Autofagie, een koekje van eigen deeg.. NATUUR TECHNIEK 1992;60:782-791
van Weely S. Studies on glucocerebrosidase and glucocerebroside metabolism in relation to Gaucher disease.. 's-Gravenhage: Pasmans Offsetdrukkerij BV; 1992. 262p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Tager JM; copromotor(s): Aerts JMFG)
Aerts JM, Sa Miranda MC, Wanzeller de Lacerda L, van Weely S, Donker-Koopman W, Brouwer-Kelder B, Jansen DC, van Leeuwen M, Schram AW, Tsiapara A, The identification of type 1 Gaucher disease patients, asymptomatic cases and carriers in The Netherlands using urine samples: an evaluation. CLIN CHIM ACTA 1991;203 (2-3):349-361 [PubMed]
Hollak CE, Aerts JM, Goudsmit R, De ziekte van Gaucher; nieuwe ontwikkelingen in de behandeling van lysosomale stapelingsziekten. NED TIJDSCHR GENEESKD 1991;135 (46):2162-2164 [PubMed]
Ohashi T, Hong CM, Weiler S, Tomich JM, Aerts JM, Tager JM, Barranger JA, Characterization of human glucocerebrosidase from different mutant alleles. J BIOL CHEM 1991;266 (6):3661-3667 [PubMed]
Rijnboutt S, Aerts HM, Geuze HJ, Tager JM, Strous GJ, Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J BIOL CHEM 1991;266 (8):4862-4868 [PubMed]
Rijnboutt S, Kal AJ, Geuze HJ, Aerts H, Strous GJ, Mannose 6-phosphate-independent targeting of cathepsin D to lysosomes in HepG2 cells. J BIOL CHEM 1991;266 (35):23586-23592 [PubMed]
Strous GJ, Geuze HJ, Aerts JM, Tager JM, Rijnboutt S. Mannose-6-phosphate independent membrane association of lysosomal enzymes occurs after passage of the Golgi complex. in: Courtnoy PJ, editor. Endocytosis. Heidelberg: Springer Verlag; 1991., p. 221-227
Aerts JM, Donker-Koopman WE, Brul S, van Weely S, Sa Miranda MC, Barranger JA, Tager JM, Schram AW, Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease. BIOCHEM J 1990;269 (1):93-100 [PubMed]
Aerts JM, Sa Miranda MC, Brouwer-Kelder EM, van Weely S, Barranger JA, Tager JM, Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease. BBA-PROTEIN STRUCT M 1990;1041 (1):55-63 [PubMed]
Sa Miranda MC, Aerts JM, Pinto R, Fontes A, de Lacerda LW, van Weely S, Barranger J, Tager JM, Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients. CLIN GENET 1990;38 (3):218-227 [PubMed]
van Weely S, Aerts JM, van Leeuwen MB, Heikoop JC, Donker-Koopman WE, Barranger JA, Tager JM, Schram AW, Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. EUR J BIOCHEM 1990;191 (3):669-677 [PubMed]
Barranger JA, Ohashi T, Hong CM, Tomich J, Aerts JMFG, Tager JM, Nolta JA, Sender LS, Weiler S, Kohn D, Molecular pathology and therapy of Gaucher disease.. JAP J INHERIT METAB DIS 1989;51:45-71
Sa Miranda MC, Aerts JMFG, Pinto RA, Barranger JA, Schram AW, Tager JM. Heterogeneity in human acid beta-glucosidase with cellulose acetate gel electrophoresis. in: Salvayre R, Douste-Blazy L, Gatt S, editors. Lipid Storage Disorders. New York: Plenum Press; 1989. 150, p. 57-65
van Weely S, Aerts JMFG, van Leeuwen M, Petersen EM, Goldblatt J, Tager JM, Barranger JA, Schram AW. Molecular properties of lysosomal glucocerebrosidase. in: Salvayre R, Douste-Blazy L, Gatt S, editors. Lipid Storage Disorders. New York: Plenum Press; 1989. 150, p. 51-57
Aerts JMFG. Biochemical studies on glucocerebrosidase in relation to Gaucher disease.. Utrecht: Drukkerij Elinkwijk BV; 1988. 342p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Tager JM, Barranger JA; copromotor(s): Schram AW)
Aerts JM, Heikoop J, van Weely S, Donker-Koopman WE, Barranger JA, Tager JM, Schram AW, Characterization of glucocerebrosidase in peripheral blood cells and cultured blastoid cells. EXP CELL RES 1988;177 (2):391-398 [PubMed]
Aerts JM, Schram AW, Strijland A, van Weely S, Jonsson LM, Tager JM, Sorrell SH, Ginns EI, Barranger JA, Murray GJ, Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. BIOCHIM BIOPHYS ACTA 1988;964 (3):303-308 [PubMed]
Sa Miranda MC, Aerts JMFG, Pinto R, Magelhaes JA, Barranger JA, Tager JM, Schram AW, Heterogeneity in human acid beta-glucosidase revealed by cellulose-acetate electrophoresis. BIOCHIM BIOPHYS ACTA 1988;965 (2-3):163-168
Tager JM, Aerts JMFG, Oude Elferink RPJ, Groen AK, Hollemans M, Schram AW. pH regulation of intracellular membrane flow. in: Haussinger D, editors. pH homeostatis, mechanisms and control. New York: Academic Press; 1988., p. 123-162
Willemsen R, van Dongen JM, Aerts JM, Schram AW, Tager JM, Goudsmit R, Reuser AJ, An immunoelectron microscopic study of glucocerebrosidase in type 1 Gaucher's disease spleen. ULTRASTRUCT PATHOL 1988;12 (5):471-478 [PubMed]
Aerts JM, Donker-Koopman WE, van Laar C, Brul S, Murray GJ, Wenger DA, Barranger JA, Tager JM, Schram AW, Relationship between the two immunologically distinguishable forms of glucocerebrosidase in tissue extracts. EUR J BIOCHEM 1987;163 (3):583-589 [PubMed]
Jonsson LM, Murray GJ, Sorrell SH, Strijland A, Aerts JF , Ginns EI, Barranger JA, Tager JM, Schram AW, Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. EUR J BIOCHEM 1987;164 (1):171-179 [PubMed]
Schram AW, Aerts JMFG, van Weely S, Barranger JA, Tager JM. Glucocerebrosidase, a membrane-associated lysosomal enzyme deficient in Gaucher disease. in: Reid E, Cook G, Luzio J, editors. Methodological Surveys in Biochemistry and Analysis. New York: Plenum Press; 1987. 17, p. 50-57
Aerts JM, Brul S, Donker-Koopman WE, van Weely S, Murray GJ, Barranger JA, Tager JM, Schram AW, Efficient routing of glucocerebrosidase to lysosomes requires complex oligosaccharide chain formation. BIOCHEM BIOPH RES CO 1986;141 (2):452-458 [PubMed]
Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, Tager JM, Schram AW, Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. CLIN CHIM ACTA 1986;158 (2):155-163 [PubMed]
Aerts JM, Donker-Koopman WE, Koot M, Murray GJ, Barranger JA, Tager JM, Schram AW, Comparison of the properties of a soluble form of glucocerebrosidase from human urine with those of the membrane-associated tissue enzyme. BBA-BIOMEMBRANES 1986;863 (1):63-70 [PubMed]
Aerts JM, Donker-Koopman WE, Murray GJ, Barranger JA, Tager JM, Schram AW, A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. ANAL BIOCHEM 1986;154 (2):655-663 [PubMed]
Aerts JMFG, Donker-Koopman WE, Koot M, Brouwer-Kelder EM, Murray GJ, Barranger JA, Tager JM, Schram AW. Forms of glucocerebrosidase present in tissues and urine. in: Freysz L, Dreyfus H, Massarelli R, Gatt S, editors. Enzymes of Lipid Metabolism II. New York: Plenum Press; 1986. 116, p. 747-752
Tager JM, Aerts JMFG, Jonsson LMV, Murray GJ, van Weely S, Strijland A, Ginns EI, Reuser AJJ, Schram AW, Barranger JA. Molecular forms, biosynthesis and maturation of glucocerebrosidase, a membrane-associated lysosomal enzyme deficient in Gaucher disease. in: Freysz L, Dreyfus H, Massarelli R, Gatt S, editors. Enzymes of Lipid Metabolism II. New York: Plenum Press; 1986. 116, p. 735-745
Aerts JM, Donker-Koopman WE, van der Vliet MK, Jonsson LM, Ginns EI, Murray GJ, Barranger JA, Tager JM, Schram AW, The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. EUR J BIOCHEM 1985;150 (3):565-574 [PubMed]
Aerts JMFG, Schram AW, Isolation of vacuoles from the upperepidermis of Petunia hybrida. I: a comparison of isolation procedures.. Z NATURFORSCH C 1985;40c (3-4):189-195
Aerts JMFG, Schram AW, Isolation of vacuoles from the upperepidermis of Petunia hybrida. II: vacuolar localization of some hydrolases.. Z NATURFORSCH C 1985;40c (3-4):196-200
Aerts JM, Lauwers AM, Heinen W, Temperature-dependent lipid content and fatty acid composition of three thermophilic bacteria. ANTON LEEUW INT J G 1985;51 (2):155-165 [PubMed]
Tager JM, Jonsson LV, Aerts JM, Elferink RP, Schram AW, Erickson AH, Barranger JA, Metabolic consequences of genetic defects in lysosomes. BIOCHEM SOC T 1984;12 (6):902-905 [PubMed]
Wintermans JFGM, van Besouw A, Bogemann G, Aerts JMFG. Galactolipid formation in chloroplast envelopes: a discussion on differences between experiments in vitro and in vivo in: Mazliak P, Costes C, Douce R, editors. Biogenesis and Function of Plant Lipids. Amsterdam: Elsevier; 1980., p. 49-56
Key publications

Witte MD, Kallemeijn WW, Aten J, Li KY, Strijland A, Donker-Koopman WE, van den Nieuwendijk AMCH, Bleijlevens B, Kramer G, Florea BI, Hooibrink B, Hollak CEM, Ottenhoff R, Boot RG, van der Marel GA, Overkleeft HS, Aerts JMFG, Ultrasensitive in situ visualization of active glucocerebrosidase molecules. NAT CHEM BIOL 2010;6 (12):907-913 [PubMed]
Aerts JMFG, Yasothan U, Kirkpatrick P, Velaglucerase alfa. NAT REV DRUG DISCOV 2010;9 (11):837-838 [PubMed]
Wennekes T, van den Berg RJBHN, Boot RG, van der Marel GA, Overkleeft HS, Aerts JMFG, Glycosphingolipids-Nature, Function, and Pharmacological Modulation. ANGEW CHEM INT EDIT 2009;48 (47):8848-8869 [PubMed]
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ, Elevated globotriaosylsphingosine is a hallmark of Fabry disease. P NATL ACAD SCI USA 2008;105 (8):2812-2817 [PubMed]
Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JEM, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM, Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. BLOOD 2011;118 (16):e118-e127 [PubMed]


All Publications

Curriculum Vitae
Hans (JMFG) Aerts is since 2000 full Professor in Medical Biochemistry of the Department of Medical Biochemistry at the Academic Medical Center of the University of Amsterdam. In 1988 he completed cum laude his PhD thesis entitled Biochemical studies on glucocerebrosidase in relation to Gaucher disease (promotores: Prof. Dr. J.M. Tager (UvA) and Prof. Dr. J.A. Barranger (USC, LA)). In 1989 Aerts was granted a research fellowship by the Royal Netherlands Academy of Sciences at the UvA, conducting studies on Gaucher disease and lysosome biogenesis at the Department of Biochemistry at the AMC. He was appointed as assistant and associate professor in the same department in 1986 and 1994, respectively. Since 2000 he as as chairman of the Department of Medical Biochemistry. 

Aerts (BKO accredited) is contributing to various teaching programmes in the faculties of Medicine and Science of the University of Amsterdam.

Aerts has been co-founder of SPHINX, the AMC’s interdepartmental collaboration on treatment and research of lysosomal storage disorders. He has acted as director of the Clinical Proteomics Facility Amsterdam (AMC-MIBITON), vice-chairman of the Amsterdam Genomics Center (UvA), chairman of the AMC Research Institute GEMO, treasurer of the Spinoza Foundation (UvA), acting chairman of AMC/UvA Zwaartepunt Metabolisme. He  is member of AMC Research Council.

As Principal investigator Aerts is in charge of the research theme Glycosphingolipids in Health and Disease. Aerts has been (co)promotor of 25 completed PhD thesis works and has published over 250 papers in peer-reviewed scientific journals. Aerts has been member of medical and scientific advisory boards of several national and internal Gaucher disease and Fabry disease patient societies. He has been inventor of over 20 granted and filed patents and scientific founder of MacroZyme and Amdix. Aerts has been chairman of the European Working Group on Gaucher Disease since 1993 and has co-organized its two-yearly symposia. He is appointed as Honory President of the EWGGD and permanent member of its board. Aerts is a recipient of the Annual Prize in Biochemistry from  the Netherlands Society of Biochemistry, the Alan Gordon Memorial Award from the Gaucher Association and the first Gaucher disease Lifetime Achievement Award  from the European Gaucher Leadership Forum.

Aerts is also part-time appointed as professor at the department of Bio-Organic Synthesis at the Leiden Institute of Chemistry of  Leiden University.

Research programmes

Prof. dr. J.M.F.G. Aerts PhD (Glycosphingolipids in health and disease)

Faculty
Prof. dr. J.M.F.G. Aerts PhD
Dr. B. Bleijlevens
Dr. D. Speijer PhD

Postdocs
Dr. E.F.C. Blommaart
Dr. M.C. van Eijk

PhD Students
Drs. R. Avagliano Trezza
Drs. W. Wegdam

Others
Ing. J.M.M. Ghauharali-van der Vlugt
Ing. A.J. de Haan
M. Mirzaian MSc
Ing. R. Ottenhoff
Ing. C.P.A.A. van Roomen
Ing. S. Scheij
Ing. M. Verhoek

Other research related activities
  • Membership of medical or scientific committee, European Working Group on Gaucher Disease, Chairnan of Gaucher network
  • Membership of medical or scientific committee, International Fabry patient society network, Member SAB
  • Membership of advisory board / Consultant, E-RARE, member SAB on behalf of The Netherlands
  • Scientific Founder, MacroZyme
  • Scientific Founder, Amdix
  • Founder, Gaucher Stichting
Current research funding
  • AMC
  • Universiteit Leiden